Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 1
SonoVue
Protocol GM&RA
CONFIDENTIAL
A Prospective Multicenter Phase III Clinical Evaluation of the Safety and 
Efficacy of Lum ason ™/SonoV ue®in Subjects Undergoing Pharm acologic Stress 
Echocardiography with Dobutam inefor the Diagnosis of Coronary Artery 
Disease
Lumason™
Protocol No.:
IND No.:
EudraCT No.:BR1-142
46,958
2015 -001962 -25
Final Version
30 April 2015
SPONSOR MEDICAL EXPERT: [INVESTIGATOR_599518] S. Dolan, MD, FECC, FESE
 
Bracco Imaging S.p.A.
Via Folli 50
[ZIP_CODE] Milan Italy 
With offices at:
Via Caduti di Marcinelle [ADDRESS_793385]/Ethics 
Committee/Regulatory Authorities/Competent A uthorities as long as they are required to keep it confidential.

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793386]/Investigational Medicinal Product ................................ ................ [ADDRESS_793387] ................................ ................................ ................................ ......24
8.4.4 Concomitant Medications ................................ ................................ ..................... 24
8.4.5 Safety  Assessments ................................ ................................ ............................... 24
[IP_ADDRESS] Adverse Events ................................ ................................ ............................... 24
[IP_ADDRESS] Physical Examination ................................ ................................ ..................... 25
[IP_ADDRESS] Vital Signs ................................ ................................ ................................ ......25
[IP_ADDRESS] Laboratory  Evaluations ................................ ................................ .................. 25
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page [IP_ADDRESS] Electrocardiograms ................................ ................................ ........................ 26
[IP_ADDRESS] Continuous Electrocardiograms ................................ ................................ .....27
[IP_ADDRESS] Pulse Oximetry ................................ ................................ ............................... [ADDRESS_793388] Echocardiograph y................................ ................................ ......................... 27
8.5.2 Pharmacologic Stress with Dobutamine ................................ ............................... 28
8.5.3 Stress Echocardiograph y................................ ................................ ....................... 28
8.6 Efficacy  Evaluations ................................ ................................ ................................ .....29
8.6.1 On-Site................................ ................................ ................................ .................. 29
8.6.2 Off-Site................................ ................................ ................................ .................. 29
8.6.3 Efficacy  Measurements ................................ ................................ ......................... 30
[IP_ADDRESS] Endocardial Border Delineation ................................ ................................ .....30
[IP_ADDRESS] LV Wall Motion ................................ ................................ ............................. 30
[IP_ADDRESS] Overall Diagnostic Conclusion ................................ ................................ ......[ADDRESS_793389] ................................ ................................ ................................ ....... 31
[IP_ADDRESS] Coronary  Angiograph y................................ ................................ ................... 31
[IP_ADDRESS] [ADDRESS_793390] Disposition and Demographic and Baseline Characteristics ........................... 41
10.2 Analy sis Population ................................ ................................ ................................ ......41
10.3 Concomitant Medications ................................ ................................ ............................. 41
10.4 Extent of Exposure ................................ ................................ ................................ ....... 42
10.5 Safety  Analysis................................ ................................ ................................ ............. 42
10.6 Efficacy  Anal ysis................................ ................................ ................................ ......... 42
10.6.1 Primary  Efficacy  Endpoint –Sensitivity  and Specificity  for Detection and 
Exclusion of CAD ................................ ................................ ................................ .42
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page [IP_ADDRESS] Truth S tandard Diagnosis ................................ ................................ ............... 42
[IP_ADDRESS] Evaluation of CAD ................................ ................................ ......................... 43
10.6.2 Co-Primary  Efficacy  Endpoint –Critical Shift of Subjects with Suboptimal 
Images to Adequate Images ................................ ................................ .................. [ADDRESS_793391]/Ethics Committee/Research Ethics Board Approval ....... 46
11.4 Financial Disclosure ................................ ................................ ................................ .....47
11.5 Safety  Monitoring Boards ................................ ................................ ............................ 47
12 Administrative Considerations ................................ ................................ ............................ 47
12.1 Regulatory  Requirements –Sponsor/I nvestigator Obligations ................................ ......47
12.2 Sponsor Regulatory  Obligations for S[LOCATION_003]Rs Reporting ................................ ............ 47
12.3 Protocol Amendment ................................ ................................ ................................ ....47
12.4 Curriculum Vitae ................................ ................................ ................................ .......... 47
12.5 Administrative Structure ................................ ................................ .............................. 48
12.6 Protocol Deviations, Violations and Exceptions ................................ .......................... 48
12.7 Monitoring Procedures ................................ ................................ ................................ .48
12.7.1 Study  Monitoring ................................ ................................ ................................ ..48
12.7.2 Case Report Form ................................ ................................ ................................ ..49
12.7.3 Inspection and Auditing ................................ ................................ ........................ 49
12.8 Archiving of Records ................................ ................................ ................................ ...49
12.9 Study  Results ................................ ................................ ................................ ................ 49
12.10 Use and Publication of Study  Results ................................ ................................ .......... 50
12.11 Financing ................................ ................................ ................................ ...................... 50
12.12 Change in Investigator ................................ ................................ ................................ ..50
12.13 Definition of the End of the Study ................................ ................................ ............... 50
12.14 Premature Termination of the Study ................................ ................................ ............ 50
12.15 Information Material ................................ ................................ ................................ ....51
12.16 Insurance Policy ................................ ................................ ................................ ........... 51
13 Confidentiality ................................ ................................ ................................ ..................... 51
14 Protocol Acceptance ................................ ................................ ................................ ............ 52
15 Refe rences ................................ ................................ ................................ ........................... 53
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793392] of Tables
Table A: Description of Investigational Product/Investigational Medicinal Product ................... 21
Table B: Laboratory  Analy tes................................ ................................ ................................ ....... 26
Table C: Overall Diagnostic Conclusion Based on L V Wall Motion ................................ .......... 31
Table D: Serious Adverse Event Reporting –Sponsor Contact [CONTACT_599467] ................................ ..35
Table E: Cross Tabulation of Dia gnosis: Truth Standard vs. Stress Echocardiograph y.............. 43
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793393] of Figures
Figure 1: Imaging Procedures ................................ ................................ ................................ ....... 29
Figure 2: 17 -Segment Model ................................ ................................ ................................ ........ 30
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793394] of Appendices
Appendix A: I nvestigational Product/I nvestigational Medicinal Product Labeling
Appendix B: L UMASON/SONOVUE Reconstitution
Appendix C: Study  Schedule
Appendix D: Serious Adverse Event Report
Appendix E: I nvestigator Statement
Appendix F: Administrative Structure
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793395] Database of European Clinical Trials
EU European Union
ºF Degrees Fahrenheit
FN False Negative
FP False Positive
FDA Food and Drug Administration
GGT Gamma -Glutamyl Transpeptidase
h Hour
IB Investigator’s Brochure
ICH International Conference on Harmonization
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793396] Com pound under investigation
IP/IMP Investigational Product/Investigational Medicinal Product
IRB Institutional Review Board
ITD Intention to Diagnose
kg Killogram
LAD Left Anterior Descending
LCx Left Circumflex
LM Left Main
LV Left Ventricle
LVEF Left Ventric ularEjection Fract ion
LVO Left Ventricle Opacification
MedDRA Medical Dictionary for Regulatory Activities
mg Milligram
MI Mechanical Index
min Minute
mL Milliliter
mmHg Millimeter of Mercury
MOD Magnetic Optical Disc
MR Magnetic Resonance
MRI Magnetic Resonance I maging
mSv Millisievert
NIMP Non-Investigational Medicinal Product
PI [INVESTIGATOR_599437] (total erythrocyte count)
RCA Right Coronary Artery
REB Research Ethics Board
ROW Rest of the World –countries outside of Americas, the Eu ropean Union, and Japan.
S Second
SAE Serious Adverse Event
SAER Serious Adverse Event Report
SAP Statistical Analysis Plan
SF6 Sulfur Hexafluoride
SPC/SmPC Summary of Product Characteristics
SPECT Single Photon Emission Computed Tomography
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TN True Negative
TP True Positive
UCA Ultrasound Contrast Agent
UE Unenhanced
UE-DSE Unenhanced -Dobutamine Stress Echocardiography 
UEUS Unenhanced Ultrasound
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 10US Ultrasound
[LOCATION_003] [LOCATION_002] of America
USP [LOCATION_002] Pharmacopeia
WBC White Blood Cell Count (total leukocyte count)
WHO World Health Organization
βHCG Beta Human Chorionic Gonadotropin
2D 2 Dimensional
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 111Title of Study
A Prospective Multicenter Phase III Clinical Evaluation of the Sa fety and 
Efficacy of Lum ason ™/SonoV ue®in Subjects Undergoing Pharm acologic Stress 
Echocardiography with Dobutam ine for the Diagnosis of Coronary Artery 
Disease
2Protocol Num ber
This study  is being conducted under prot ocol number: BR1 -142.  
IND number: 46,[ADDRESS_793397] number: 2015 -001962 -25.
3Introduction
Stress echocardiograph y is an established imaging modality  for the detection of coronary  artery  
disease (CAD).1,2,3,4,5,6,7The primary  indication for conventional stress echocardiograph y is to 
indirectly detect angiographically  significant ( ≥50% diameter) stenoses b y inducing ischemia or 
to assess the patient’s risk for a cardiac event.5,8,9,10Increasingl y stress echo techniques have been 
shown to offer valuable prognostic in formation in the risk evaluation of stable chronic 
CAD .5,10,11Significant studies (> 100 patients) of dobutamine stress echocardiograph y (DSE) 
show a range for sen sitivity  of between 61 –95%, while that for specificity  ranged from 51 –
95%11for the diagnosis of CAD.1The detection of CAD with stress echocardiograph y is based 
onthe observation of contractile d ysfunction in any  myocardial segment at rest or with stress; 
therefore, complete visualization of all left ventricular (LV) endocardial borders (EB) is 
necessary  to document or exclude abnormalities of regional my ocardial w all thickening 
confidently .12,13Interpretation of wall thickening is qualitative, highl y dependent on the skill and 
experience of the reviewing ph ysician, and is affected considerabl y by [CONTACT_599468] (EBD).12,13Numerous patient factors may produce suboptimal images with 
poor EBD. Given, in addition, the challenges imposed by  [CONTACT_599469], non -diagnostic or poor -quality  images may  occur 
in up to 30% of patients.12,13The advent of digital side -by-side analy sis, standardized reporting 
criteria, and generalized use of tissue harmonic imaging has reduced, but not overcome, this 
problem.[ADDRESS_793398] agents (UCAs) has shown to improve EBD during stress 
echocardiograph y and is re commended for use in patients with poor unenhanced image quality  
by [CONTACT_599470] (ASE) and the European Association of 
Echocardiograph y (EAE).12,13  However, while Luma son™ (sulfur hexafluoride lipid-type A
microsphere s)with an approved trade name [CONTACT_599519] /SonoVue® (sulfur hexafluoride 
microbubbles) with an approved trade name [CONTACT_599520] ,is approved for use in echocardiograph y both at rest and stress in the 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 12European Union (EU) and Canada , no UCA is currently  approved in the [LOCATION_002] of 
America ([LOCATION_003]) for use in stress echocardiography  to improve LV EBD in patients with 
suboptimal unenhanced imaging.
Although generalized use of tissue harmonic imaging has improved image quality , interpretation 
of stress echocardiograms may  still be limited in patients with poor acoustic windows .12,[ADDRESS_793399] -enhanced 2 dimensional (2D) echocardiography  with 
harmonic imaging had excellent correlation with radionuclide, magnetic resonance (MR) and 
computed tomographic (CT) measurements of LV volumes and left ventricular ejection fraction 
(LVEF) with improved inter -observer agreement and phy sician interpretation confidence 
compared to unenhanced harmonic imaging in adult population.15,16Increasing accuracy  of 
LVEF measurements have been associated with contrast -enhanced ha rmonic imaging over 
unenhanced harmonic imaging and fundamental imaging, respectivel y.17,18
Non-diagnostic or poor -quality  images may  occur in up to 30% of patients during stress because 
of challenges imposed b y excessive cardiac motion due to hyperventilat ion and tachy cardia at 
peak stress.  There are documented benefits through published data regarding the value of the use 
of contrast agents in stress echocardiograph y with respect to improvement in image quality  and 
EBD, which further translates into enhan ced interpretation of regional and global function with 
decreased inter -and intra -observer variabilit y.4,[ADDRESS_793400] and peak stress across a range of unenhanced baseline 
image quality  (i.e., greatest improvement is seen in patients with the poorest basel ine 
images) with completeness of wall -segment visualization, at both rest and peak stress.6,19The 
ASE1and American College of Cardiology (ACC)20recommendations for u se of contrast 
enhancement in stress testing have been supported by  [CONTACT_599471].
1,4,6,19,20
Due to the increased routine use of DSE as a non -invasive cardiac imaging tool in adu lts with 
suspected or known CAD for the detecti on and /or evaluation of CAD and an increasing number 
of suboptimal, non -diagnostic quality  images mostly  with respect to the challenges imposed by  
[CONTACT_599472] , we aim to study  
the saf ety and efficacy of L UMASON -enhanced stress echocardiography  with dobutamine in 
subjects with suboptimal LV EBD at unenhanced echocardiograph y.  This study  isbeing 
conducted as part of the Phase III program in sup port of a supplemental New Drug Application 
(sNDA) to be filed with the Food and Drug Administration ( FDA ).
4Study Objectives
Primary  Objectives:
To assess the efficacy  of LUMASON -enhanced dobutamine stress echocardiograph y(DSE)
in subjects with suspected or known CAD having suboptimal left ventricular ( LV) 
endocardial border delineation (EBD )at unenhanced echocardiography  in terms of:
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 13Sensitivity  and specificity  for the detection or exclusion of CAD in unenhanced versus 
LUMASON -enhanced DSE using coronary angiography  or clinical follow -up as the 
truth standard;
Critical shift from suboptimal (≥2 adjacent segments inadequate on an y api[INVESTIGATOR_599438]) at 
unenhanced dobutamine stress echocardiograph y (UE -DSE) to adequate images 
(reduction of suboptimal adjacent s egments) for LV EBD at contrast -enhanced 
dobutamine stress echocardiograph y (CE -DSE).
Secondary  Objectives:
Change from peak stress non -contrast ultrasound (UE-DSE) versus peak stress contrast -
enhanced ultrasound (CE-DSE) in total L VEBD score.
To obtain saf ety data in subjects undergoing DSE with LUMASON .
5Investigational Plan
5.[ADDRESS_793401] and that are scheduled for 
coronary  angiography . Suboptimal L V EBD is defined as published in guidelines, having ≥[ADDRESS_793402] echocardiogram (UEUS) 
with the standard api[INVESTIGATOR_2855] [ADDRESS_793403] 
enhanced echocardiography (CEUS) .  A recording of 2D transthoracic harmonic 
echocardiograph y images will be performed for both UEUS and CEUS rest imag ing. At least [ADDRESS_793404] unenhanced echocardiograph y (UEUS) and contrast 
enhanced -echocardiography  (CEUS) the d obutamine infusion will begin.  Once peak stress is 
achieved (with or without the additi on of atropi[INVESTIGATOR_050]), subjects will undergo unenhanced 
dobutamine stress echocardiograph y (UE -DSE).  This will be followed by [CONTACT_599473] -enhanced 
dobutamine stress echocardiograph y (CE -DSE) with the administration of [ADDRESS_793405] 
from the unenhanced (UEUS and UE -DSE) and contrast -enhanced (CEUS and CE -DSE)
echocardiographic images .  
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793406] ’s clinical information . 
The efficacy  anal ysis will be based on the blinded reader evaluations of LV EBD, wall motion 
abnormalities and diagnosi s of CAD .
A fourth blinded reader will assess the coronary  angiography  images and provide a diagnosis of 
CAD. The fourth reader will be blinded to the specifics of the protocol including the patient 
population and the results of the ultrasound examination , but will receive clinical information 
such as the medical history  on the subject .  
Safety  will be evaluated in this study  by [CONTACT_599474], vital signs, electrocardiograms (discrete & cont inuous), laboratory  
tests and continuous pulse oximetry .
This study  is planned to be conducted in the [LOCATION_002], Canada and Europe.
5.2 Discussion of Study Design
The use of UCAs has shown to improve EBD during stress echocardiography  and is 
recommended fo r use in patients with poor unenhanced image quality  by [CONTACT_599475].12,13,21However, while LUMASON (under the trade name [CONTACT_599521]) is approved for use i n 
echocardiograph y both at rest and stress in the EU, no UCA is currentl y approved in the [LOCATION_003] for 
use in stress echocardiograph y to improve LV EBD in patients with suboptimal unenhanced 
imaging. 
The mechanism of action of LUMASON during stress echocardiog raphy  would be exactly  the 
same as during an exam at rest. LUMASON would be used in subjects with suboptimal images 
to enhance the LV cavity and improve the detection of the EB. This Phase III study  will, 
therefore, be conducted with a consistent design (d ose, study  population and endpoints of both 
LV EBD score and Sensitivity /Specificity  for detection of CAD ) based on the Phase III studies 
previously  conducted to obtain approval for the use of LUMASON in echocardiography  at 
rest22,23,24and a previous large, multicenter, dose -ranging study  of LUMASON in stress 
echocardiograph y25.
The study  is designed to assess the safety  and efficacy  of LUMASON at improving the 
visualization of the L V EBD during pharmacologic stress echocardiography  examinations and 
for detec tion or exclusion of CAD .  
Thestudy  population will consist of adult subjects referred for pharmacologic stress 
echocardiograph y and with suboptimal image quality  during unenhanced ultrasound imaging at 
restwho have known or suspected CAD . Subjects to be enrolled in the current study  are 
representative of subjects who could benefit most from CEUS stress echocardiograph y.
Imaging conditions will be representative of those used in routine clinical practice and will 
include LV EBD using harmonic imaging mod ality. Each subject will undergo anunenhanced
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 15echocardiogram ( UEUS )followed b yaLUMASON -enhanced echocardiogram (CEUS) both at 
rest. The same appl iestothestress echocardiogram when echocardiographic images will be 
obtained immediately  after dobutamin eadministration (UE-DSE) and then LUMASON will be 
administered and LUMASON -enhanced stress images (CE-DSE) will be captured. Thus, each 
subject will serve as its own control and is designed as anintra-patient controlled study .
The current guidelines of A merican Heart Association (AHA)26and ASE12while they suggest 
ultrasound contrast use in difficult to image patients with suboptimal image quality  at their 
presenting rest echocardiograph y exams, their definiti on of a suboptimal study is when [ADDRESS_793407] 3 api[INVESTIGATOR_320766]. The same criteria 
will be applied in adults during peak stress imaging, representative of those used in routine 
clinical practice and will incl ude assessment of LV EBD using harmonic imaging modalit y.
Taking into consideration the clinical importance, both the diagnostic performance and the LV 
EBD visualization are defined as co-primary  efficacy  endpoints for the study .  
First co-primary  efficac y endpoint is a comparison of diagnostic performance ( sensitivity  
and specificit y)for the detection or exclusion of CAD in unenhanced (UE -DSE) versus 
Lumason -enhanced DSE (CE -DSE) using coronary  angiography or clinical events based 
on [ADDRESS_793408] one vessel with stenosis ≥ 50% based on the assessment of off -
site reader for coronary  angiography  or have one of the clinical events (cardiac death, 
non-fatal m yocardial infarction , revascularization and need for revascularization ) within 
the 6 month follow -up.
Second co-prim ary efficacy  endpoint is critical shift from suboptimal ( ≥2 adjacent 
segments inadequate on any  api[INVESTIGATOR_599438]) at unenhanced dobutamine stress 
echocardiograph y (UE-DSE) to adequate images (reduction of suboptimal adjacent 
segments) f or LV EBD at contrast -enhanced dobutamine stress echocardiograph y (CE -
DSE).
The secondary  efficacy  endpoint of L UMASON studies (change from baseline in total of L V 
EBD score) is the same endpoint for adult studies for LV EBD indication at rest echo 
examina tions.
The muscle and cavit y of the L V will be divided into 17 segments (17 -segment model).  The 
17-segment model will be util ized as recommended by  [CONTACT_455983] g uidelines.1,12,[ADDRESS_793409] and stress.26  The clinical utility  of improvement in L V EBD resulting 
from opaci fication of the LV as an aid in determination of more clinicall y relevant parameters is 
recognized b y the 2008 ASE consensus statement as leading to improvement in feasibility, 
accuracy , and reproducibility  of echocardiography for the qualitative and quant itative assessment 
of LV structure and function.12
Unevaluable image are defined as images with inadequate visualization of segments comprising 
all coronary  artery  territories due to 1 or more of the following artifacts: motion artifacts, lateral 
wall drop out, swirling or attenuation artifacts.  From the published literature6and previous 
Bracco -sponsored study258% of the UE -DSE images are expected to be unevaluable.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793410] on beta -2 or alpha receptors. I n the [LOCATION_003], dobutamine is indicated 
when parenteral therap y is necessary  for inotropic support in the short -term treatment of patients 
with cardiac decompensation due to depressed contractility  resulting either from organic heart 
disease or from cardiac surgical procedures. In the EU and other countries, dobutamine is also 
indicated for use in stress echocardiograph y as an alternative to exercise in patients for whom 
routine exercise cannot be satisfactoril y performed. Even if not approved for use in stress 
echocardiograph y in the [LOCATION_003], dobutamine is recommended as the pharmacologic stressor of 
choice for stress echocardiograph y by [CONTACT_599476]20Criteria Task 
Force, the ASE, and the AHA.1,26Dobutamine became the preferred stressor in [LOCATION_003] as the 
AHA/ACC guideline s stated that “dobutamine stress echo has higher sensitivity  than vasodilator 
stress echo for detection of CAD.”28,29The recent 2007 recommendations on stress 
echocardiograph y of the ASE conclude that “although vasodilators may have advantages for 
assessmen t of m yocardial perfusion, dobutamine is preferred when the test is based on 
assessment of regional wall motion.”[ADDRESS_793411] ’s clinical 
information .Blinded off -site assessments are used to evaluate diagnostic agents in order to 
eliminate the potential bias associated with on -site assessments due to the investigator’s 
knowledge of the subject ’s medical history , clinical findings from other modalities, or other 
clinical information. Thus, the off -siteassessments allow for a blind edevaluation of efficacy  
which isnot possible for the on -site assessments.
All subject s will have a tru thstandard of either coronary  angiograph y or,if coronary  
angiograph y is indeterminate or not performed ,they will be followed for up to [ADDRESS_793412] cardiac events .Although we will study the sensitivity  and specificity  in detecting 
anatomic stenoses ≥50% in severity , not all th e subject s will undergo coronary  angiography . 
Therefore, subject s who do not undergo coronary  angiograph y in the stud y will be followed for 
cardiac events ( cardiac death, non -fatal my ocardial infarction, revascularization and need for 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 17revascularization) at6month s.  The proposed cardiac events as hard end points in the study  are 
widely  used, well recognized ,robust ,measurements of a non -invasive test to predict cardiac 
events .5,7,[ADDRESS_793413] to provide a centralized reading for the confirmation of the diagnosis of 
CAD. He/she will be blinded to the results of the stress echo examination. Medical historical 
information will be provided to the reader. This will allow the gold standard to achieve the 
maximum accuracy  and reliability . It will also serve to reduce the variability  of readings 
performed b y many different unblinded readers on -site across all stud y sites.
5.2.[ADDRESS_793414] on image 
quality  on the equipment side, approximately  30% of patients conti nue to undergo stress 
echocardiographic examinations that are non -diagnostic or inconclusive due to poor image 
quality , with subsequent poor evaluation of cardiac function, leading to the need for more 
invasive techniques.1,12,[ADDRESS_793415] agents, cannot be 
excluded, and there is potential for unpredictable, serious hy persensiti vity reactions, including 
anaph ylactoid reactions. Further, such reactions may  lead to life -threatening conditions if they  
occur in critically  ill patients. However, serious hy persensitivity  reactions after LUMASON 
administration are rare (estimated occurr ence of approx. 1 in 10,000 exposures) and suboptimal 
EBD and inaccurate assessment of L V function (global and regional wall motion assessment) 
and/or cardiac anatom y are frequent in a patient population with suspected CAD .12,13,31
Echocardiograph y is an imaging modalit y that represents a fundamental investigation used in the 
initial and ongoing management of patients with suspected or known CAD because it is 
noninva sive, provides e asy access, any time and any  day, can be performed at the bedside of the 
patient, and can be repeated as often as needed for monitoring. The balance of the benefit of 
LUMASON in comparison with its risks is also positively  affected by [CONTACT_599477]1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 18care settings and ph ysicians that can promptl y and effectivel y recognize and manage serious 
adverse events.
Although optional noninvasive modalities (SPECT, CMRI  and CT angiography ) may  provide 
diagnostic accuracy , valuable and detaile d data, all of them pose greater risk than transthoracic 
echocardiograms .3233Probably  the most critical drawback is the time delay  in obtaining the data 
needed for urgent risk assessment and treatment, but safet y concerns including exposure to 
radioactive material and risky  patient transportation to the nuclear/MRI department are also 
present.21Furthermore, if an imaging agent is used, these imaging modalities carry the same risk 
of rare, serious h ypersensitivi ty reactions and the same risk of serious, life -threatening 
complications.
Of note, at the patient level, the effective dose of a single nuclear cardiology stress imaging scan 
ranges from [ADDRESS_793416] X-rays 
[Cardiolite®(Tc-99m Sestamibi )], [ADDRESS_793417] X -rays (Thallium) and [ADDRESS_793418] X -rays (with 
dual imaging protocol) .  According to the latest estimates the risk of cancer for a middle aged 
patient ranges from 1 in 1000 (for Cardiolite) to 1 in 400 (for a dual isotope scan).21Therefore, 
contrast -enhanced stress echocardiography  should be preferred due to wider availability  and for 
its radiation free nature.  Overall , the effectiveness and suitability  of LUMASON as a contrast 
agent for use with echocardiograph y to obtain improve LV EBD has been demonstrated. 
Clinical studies have shown LUMASON to be safe and well tolerated with minimal risk to 
subject s. In conclusion , the benefit -to-risk ratio for LUMASON is high, indicating an advantage 
to subject s undergoing stress echocardiograph y.
With the marked increase in costs associated with cardiovascular care and interventions, it is 
vital that non -invasive imaging procedures be highl y accurate in detecting whet her a patient is at 
risk for coronary  events, not just whether they  have a significant coronary  stenosis. I t is also vital 
that these stress imaging procedures be equally  accurate in identify ing which patients are at risk 
for future cardiac events. 
5.[ADDRESS_793419] data (coronary  angiography orcardiac events )as described in Section 8.6.[ADDRESS_793420].  If the overall y ield of positive CAD subjects is lower than the assumed 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 1930%,34then additional subjects will need to be enrolled in order to obtain a sufficient number of 
positive CAD subjects.
5.4.[ADDRESS_793421] meets the following inclusion criteria:
Provide s written Informed Consent and iswilling to comply  with protocol requirements ;
Is at least 18 years of age;
Has suspected or known CAD and is scheduled to undergo coronary  angiography  within 6 
months after the LUMASON DSE.
Has undergone a previous echocar diograph y prior to enrollment; result ing in suboptimal 
unenhanced images at rest, defined as ≥ [ADDRESS_793422] does not fulfill the inclusion criteria, or if any  of 
the following conditions are observed:
Is a pregnant or lactating female. Exclude the possibility  of pregnancy :
by [CONTACT_599478] (s erum or urine βHCG) within 24 hours prior to the 
start of LUMASON administration (s),
by [CONTACT_599479]  (e.g., tubal ligation or hy sterectomy ),
post menopau sal with a minimum 1 y ear without menses;
Has an y known h ypersensitivity  to 1 or more ingredients of LUMASON (sulfur 
hexafluoride or to an y components of LUMASON );
Has an y known h ypersensitivity  to dobutamine;
Has a n ongoing or recent (within the last 30 d ays)acute m yocardial infarction ;
Has kn own right -to-left, bidirectional or transient cardiac shunt (ruled out with agitated 
saline study  performed before administration of LUMASON );
Has electroly te (especially  potassium and magnesium) abnormalities;
Has u nstable pulmonary  and/or sy stemic hemodynamic conditions e.g.:
decompensated or inadequately  controlled congestive heart failure (NYHA Class I V); 
hypovolemia; 
uncontrolled hy pertension, i.e. resting systolic blood pressure >200 mm Hg or d iastolic 
blood pr essure >110 mm Hg; 
unstable angina; 
acute coronary  syndrome;
aortic dissection; 
acute pericarditis, 
myocarditis, or endocarditis;
stenosis of the main left coronary  artery ; 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 20hemody namicall y significant outflow obstruction of the left ventricle, includ ing 
hypertrophic obstructive cardiom yopath y; 
hemody namicall y significant cardiac valvular defect; 
acute pulmonary  embolism;
Has uncontrolled cardiac arrh ythmias;
Has significant disturbance in conduction; 
Has h ypertrophic subaortic stenosis ;
Has an a cute illness (e.g., infections, hy perthy roidism , or severe anemia) ;
Was previously  entered into this study  or received an investigational compound within 30 
days before admission into this study ;
Has been treated with any  other contrast agent either intravasc ularly or orally  within [ADDRESS_793423] LUMASON administration;
Has an y medical condition or other circumstances which would significantly decrease the 
chances of obtaining reliable data, achieving study  objectives, or completing the study  
and/or pos tdose follow -up examinations;
In addition, d ue to the use of Atropi[INVESTIGATOR_599439] d targeted heart rate with 
peak dobutamine infusion, subjects with the following will be excluded:
Glaucoma;
Pyloric stenosis; 
Prostatic hy pertrophy .
5.4.[ADDRESS_793424]’s discontinuation on the Case Report Form (CRF) . 
Discontinued subjects are not replaced.  Discontinue a subject from the study  if the subject:
Withdraws consent;
No longer meets the Inclusion Criteria;
Experiences an y of the Exclusion Criteria;
Has an adverse event that ,in the opi[INVESTIGATOR_2511] I nvestigator, requires the subject’s 
discontinuation. Perform subject follow -up in accordance with Section 9.1.[ADDRESS_793425] /Investigationa l Medicinal Product
The investigational product (I P)/investigational medicinal product (IMP) is 
LUMASON /SONOVUE . 
In the [LOCATION_003] and Canada, LUMASON will be supplied as asingle 3-part kit with the following 
components:
1clear glass vial labeled as LUMASON ( sulfur hexafluoride lipid -type A microsphere s) 
for injectable suspension,
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 211prefilled syringe containing 5 mL Sodium Chloride 0.9% Injection, USP (Diluent) and 
its plunger rod
1Mini -spi[INVESTIGATOR_599440], SONOVUE will be supplied in a kit which includes 2 indiv idual plastic containers 
each with the following components:
1 vial containing 25 mg of ly ophilized powder labeled as SONOVUE
1 pre-filled s yringe containing 5 mL sodium c hloride NaCl 0.9%w/v and its plunger rod
1 MiniS pi[INVESTIGATOR_599441] s ystem
6.1 Description and Labeling
LUMASON is formulated as a 25 -mg sterile, non-pyrogen iclyophilized powder in a septum -
sealed vial. The ingredients in each vial of LUMASON ,after reconstitution, are listed in Table A
Table A: Description of Investigat ional Product /Investigational Medicinal Product
Ingredient Concentration / Am ount per Unit
Polyethylene glycol (PEG) 4000 4.91 mg/ml
Phospholipi[INVESTIGATOR_805] (DSPC/DPPG 1:1 w /w) 0.075 mg/ml 
Palmitic Acid 0.008 mg/ml
Sulfur Hexafluoride (SF6) 8 µL/ml *
*Contents in the microspheres/microbubbles
Each vial of LUMASON will bear a two -part label with the information detailed in Appendix A.
Affix the second part of the two -part label from the vial to the vial label page .
6.2 Storage
Store theLUMASON kits at controlled r oom temperature at 25°C (77°F) excursions are 
permitted to 15 -30 °C (59 -86°F ).  No special storage conditions are required for SONOVUE
containers .  Do not freeze.  All kits /containers must be stored in a secure area with limited 
access.
6.3 Blinding and Random ization
This is an open -label, nonrandomized study .
6.4 Handling and Preparation
Prior to administration, the ly ophilized powder should be reconstituted under aseptic technique
conditions by  [CONTACT_599480] 5 mL sodium chloride s yringe into the 
LUMASON /SONOVUE vial .After adding the sodium chloride solution, the vial should be 
shaken vigorousl y for 20 seconds, after which a homogeneous white milky liquid is obtained. 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 22Detailed instructions for the reconstitution of both LUMASON and SONOVUE are presented in 
Appendix B.  
Store the reconstituted IP/IMPat room temperature in the vial supplied. Although the suspension 
is useable for up to 3 hours in the [LOCATION_003] and up to 6 hours in Canad a/Europe the more 
conservative time period of 3 hours will be used in this study .Upon standing for more than 15 
minutes, buoy ancy  causes some of the larger microspheres /microbubbles to rise to the surface. 
Therefore, gently  agitate the reconstituted vial in a top -to-bottom manner to resuspend the sulfur 
hexafluoride microspheres /microbubbles before administration.
A separate kit /container should be used for the rest (CEUS) and stress (CE -DSE) LUMASON 
administrations. In the case of incomplete use of vial contents, the product cannot be reused.
6.[ADDRESS_793426] examination, and then again as a single 2 mL bolus injection after peak stress is achieved 
with the administration of the stress agent, dobutamine (with or without the addition o f atropi[INVESTIGATOR_050]) , 
and the UE -DSE stress examination is completed.  Each LUMASON injection will be performed 
intravenously  through a peripheral line using a [ADDRESS_793427] and the stress LUMASON injections.
6.6 Accountability
In accordance with International Con ference of Harmonization (I CH) and [LOCATION_002] (US)
FDA requirements, the Investiga tor and/or Drug Dispenser must at all times be able to account 
for all IP/IMPfurnished to the institution.  The appropriate site personnel must sign, date and 
immediately  forward to the Sponsor the IP/IMPreceipt form included with each shipment.
No IP/IMP is to be used outside of this study .  Record the use of the IP /IMPon the appropriate 
Drug Accountability  Record .  All containers of IP/IMPmust be accounted for, whether used or 
unused, during the course of and at the conclusion of the study .  At the conclusion of the study , 
all shipments of I P/IMPto the I nvestigator must be returned to the Sponsor accompanied by  a 
completed, signed cop y of the appropriate IP /IMPi[INVESTIGATOR_599442].
7Non-Investigational Medicinal Products
7.[ADDRESS_793428] (NIMP) in this study  due to its use as the 
pharmacologic stress agent during stress echocardiographic imaging .Refer to the dobutamine 
Package Insert ( PI)/Summary  of Product Characteristics ( SPC)for details on the storage, 
handling, preparation and administration.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793429] (NIMP) in this study  due to its use as an 
adjunct to dobutamine in achieving peak stress during DSE . Refer to the atropi[INVESTIGATOR_599443]/SPC for 
detai ls on the storage, handling, preparation and administration.
8Methodology
8.[ADDRESS_793430] ( IRB)/Ethics Committee ( EC)/Research Ethics Board ( REB )
(including specific local requirements e.g., data protection where applicable).   Give the subject a 
copy  of the signed and dated written informed consent form including any other written 
information regarding the study . Document the Informed Consent process in detail in the source 
record at the site.
8.[ADDRESS_793431] enrolled and incrementing 
by “1” for each sequential subject.
For example, at site 01, the investigative site will assign the first subject 0101; th e second subject 
0102, etc.
Never reassign subject numbers.   In the event that a subject withdraws from the study , the 
number assigned to that subject is retired and the next subject receives the next sequential 
number.
8.[ADDRESS_793432] (including; height, weight, age, sex and race) 
and record on the CRF.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793433]’ s medical history /cardiac history  on the 
appropriate Medical History  or Cardiac Medical History  sections of the CRF.
8.4.[ADDRESS_793434] is female ,and of child bearing potential, exclude the possibility  of pregnancy :
by [CONTACT_6310] (serum or urine βHCG) within 24 hours prior to the start of IP/IMP
administration;
by [CONTACT_599479]  (e.g., tubal ligation or hy sterectomy );
post-menopausal wit h a minimum of [ADDRESS_793435] all medications (prescription and over -the-counter) taken within [ADDRESS_793436] on the 
concomitant medication CRF page.
8.4.5 Safety Assessments
[IP_ADDRESS] Adverse Events
Monit or subjects for an y untoward medical occurrences from the time of sign ing of Informed 
Consent through [ADDRESS_793437] ed at the 24 hour 
postdose visit with a follow up phone call /contact [INVESTIGATOR_136] [ADDRESS_793438] medical 
occurrences as a result of the administration of the NIMP(s)(dobutamine or atropi[INVESTIGATOR_050]) will also 
be considered adverse events.  However, the known respon se pattern resulting from the 
administration of NIMP(s)for the purpose used in this study  will not be recorded as adverse 
events . 
Record all untoward medical events in the Adverse Event section of the CRF as specified in 
Section 9.  Only  postdose untowar d medical occurrences will be tabulated as adverse events.
All serious adverse events that occur during the study  monitoring period are required to be 
collected regardless of the relationship to LUMASON or the NIMPson the Serious Adverse 
Event Report (SAE R) Form .
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 25In addition, theinvestigator should report an y serious adverse events that occur after the 
monitoring period that he/she believes may  be related to the LUM ASON or the NIMPson the 
SAER Form.
[IP_ADDRESS] Physical Examination
Perform a ph ysical examination wit hin [ADDRESS_793439]’s baseline physical examination will be recorded on the 
Medical/Phy sical exam section of the CRF.
[IP_ADDRESS] Vital Signs
Collect blood pressure and heart rate at the time points listed below.  Obtain all the vital signs in 
a position that is consistent for all time points for each subject.
Rest echocardiograph y: within [ADDRESS_793440] LUMASON (CEUS) administration
[ADDRESS_793441] L UMASON (CEUS) administration
Stress echocardiograph y: immediately  prior to the Stress L UMASON (CE-DSE)
administration
30 minutes after the Stress L UMASON (CE-DSE) administration
1 hour after th e Stress LUMASON (CE-DSE) administration*
24 hours after the Stress LUMASON (CE-DSE) administration*
*If stress echocardiograph y (CE -DSE) is not performed, obtain vitals at [ADDRESS_793442] LUMASON administration.
[IP_ADDRESS] Laboratory Evaluations
Collec t blood samples within [ADDRESS_793443] LUMASON administration.  A central laboratory   will perform evaluations for the 
analytes listed in Table B:
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 26Table B: Laborator y Analytes
Hem atology Clinical Che mistry Cardiac Biom arker
Hem atocrit Sodium AST/SGOT Cardiac Troponin
Hem oglobin Potassium ALT/SGPT
RBC count Chloride Alkaline 
Phosphatase
WBC count Glucose GGT
differential WBC count Urea Nitrogen Uric Acid
Platelets Creatinine Total Protein
Total Bilirubin Albumin
LDH Calcium
Magnesium
Prepare blood samples and ship via overnight courier per the Instruction Manual provided by  [CONTACT_19979] .
[IP_ADDRESS] Electrocardiograms
A 12 -Lead electrocardiogram ( ECG )will be performed in all subjects at the following time 
points:
Rest echocardiograph y: within [ADDRESS_793444] LUMASON (CEUS) administration
[ADDRESS_793445] LUMASON (CEUS) administration
Stress echocardiograph y: immediately  prior to the Stress LUMASON (CE-DSE)
administration
30 minutes after the Stress LUMASON (CE-DSE) administration
1 hour after the Stress LUMASON (CE-DSE) administration *
24 hours after the Stress LUMASON (CE-DSE) administration *
*If stress echocardiography (CE-DSE) is not performed, obtain ECGs at [ADDRESS_793446] LUMASON (CEUS) administration.
ECG examinations will be evaluated b y a central ECG laboratory  that will provide the ECG 
equipment to the site and will employ  a cardiologist to perform the cent ralized ECG evaluation 
containing the following information:
RR interval
PR interval
QRS interval
QT and QTc interval (Bazett’s and Fridericia’s)
Overall diagnostic assessment
Comparison to Baseline
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 27Attach a photocop y of the ECG reports to the appropriate page of the CRF . A dual snap electrode 
will be supplied to the site by [CONTACT_599481] (static) 12-lead ECGs and continuous ECG monitoring described in section [IP_ADDRESS] .
[IP_ADDRESS] Continuous Electrocardiog rams
Continuous ECG monitoring will be performed starting [ADDRESS_793447] 
administration of L UMASON (CEUS) and will continue through [ADDRESS_793448] 
administration of L UMASON.
Continuous ECG ex aminations will be evaluated on site by [CONTACT_737].
[IP_ADDRESS] Pulse Oximetry
Pulse oximetry  will be monitored starting at [ADDRESS_793449] administration of 
LUMASON (CEUS) and continuing through [ADDRESS_793450] LUMASON 
administration (CE-DSE) .  
Pulse oximetry  will be evaluat ed by [CONTACT_21639] -site Investigator. 
8.5 Imaging Procedures
At each site, the same commercially  available echocardiographic equipment and transducers will 
be used for all subjects. Subjects will be examined in either the supi[INVESTIGATOR_599444]. The t ransmit power ( ≤ 0.8 MI) and the gain setting will be adjusted at the beginning of 
each procedure to obtain optimal endocardial visualization. Both settings must be kept constant 
throughout each subject’s evaluation. Focus will be set at the far field belo w the mitral valve. 
Every  effort must be made to keep the optimal transducer position for standard views. At each 
site, imag e acquisition should be performed b y the same sonographer throughout each subject’s
study .See Figure 1for theorder of imaging pr ocedures.
Both the rest ( UEUS and CEUS ) and the stress (UE -DSE and CE -DSE) examinations must be 
identified by  [CONTACT_599482] I maging Manual. The investigational sites are also 
required to maintain a copy  of the subject’s examination as a record of the study .
Prior to restadministration of LUMASON (CEUS) , further evaluation for intracardiac shunt will 
be demonstrated with agitated saline study  toassess the interatrial septum ,unless an intracardiac 
shunt has been previously ruled out. If no evidence of intracardiac shunt is confirmed b y the 
cardiologist, the subject will further undergo a CEUS echocardiograph y examination.
8.5.[ADDRESS_793451] CEUS images, 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793452] 30 minutes 
after the restLUMASON administration starting at a rate of 5µg/kg/min. At 3 min ute intervals, 
the infusion rate can be increased to 10, 20, 30, and 40 µg/kg/min to reach one of the following 
peak stress endpoints:
Target heart rate :  0.85x (220 -age);
Development of new or worsening regional wall motion abnormalities;
Peak dose;
Significant arrh ythmias;
Severe h ypertension (s ystolic blood pressure >200 m mHg or diastolic blood pressure >110 
mmHg);
Hemody namicall y significant h ypotension;
Intolerable s ymptoms.
If a peak stress endpoint isreached, the test can be stopped before reach ing the maximal dose of 
dobutamine. If no peak stress endpoint isreached after the maximum dose of dobutamine, 0.[ADDRESS_793453] followed by  [CONTACT_599483][INVESTIGATOR_2855] 2 -and 3-chamber views .
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 29Figure 1: Imaging Procedures
8.6 Efficacy Evaluations 
8.6.1 On-Site
The on -site Investigators will provide an overall diagnosis of CAD (Section [IP_ADDRESS] )for eac h 
subject based on wall motion abnormalities from the results of the unenhanced (UEUS & UE -
DSE) and contrast -enhanced (CEUS and CE -DSE) echocardiographic images .
8.6.2 Off-Site
The off -site efficacy  evaluations of the echocardiographic images will be performed b y 3 
independent, experienced readers, unaffiliated with the investigational sites and blinded to an y 
clinical information for subjects enrolled in this study .  These off-site blinded readers will score 
EBD (Section [IP_ADDRESS] ), LV wall motion (Section [IP_ADDRESS] )and overall diagnostic conclusion 
(Section [IP_ADDRESS] ).
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793454] does not complete the echocardiography  examination s(rest, stress or an y views are 
missing) the subject will not be included in the efficacy  evaluation for on -or off-site.
[IP_ADDRESS] Endocardial Border Delineation
The assessment of EBD will be performed b y dividing the heart into [ADDRESS_793455] api[INVESTIGATOR_2855] 4 -, 2-, and 3 -chamber views (see Figure 2) according to the ASE1,12,27guidelines:
Figure 2: 17-Segment Model
LV EBD will be graded for each segment of the 17 -segment model shown in Figure 2by [CONTACT_599484]-site reader using the following 3 -point scale:
0 = Inadequate (endocardial border not visible)
1 = Sufficient (endocardial border barel y visible)
2 = Good (endocardial border clearl y visible)
For LV EBD ,separate assessments will be collected for th e unenhanced ( UE-DSE )and contrast -
enhanced ( CE-DSE )images at peak stress .  
[IP_ADDRESS] LV Wall Motion
LV wall motion will be graded b y each off -site reader using the following 3-point scale at rest 
and peak stress for unenhanced (UEUS and UE -DSE) and contrast -enhan ced (CEUS and CE -
DSE) images:
1 = Normal
2 = Abnormal (Mild -Moderate, Severe Hy pokinesis , Akinetic and/or Dy skinetic)
3= Unevaluable
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page [IP_ADDRESS] Overall Diagnostic Conclusion
The overall diagnostic conclusion will be determined by  [CONTACT_599485]-site Investigator and the off-site 
reader using the scoring sy stem in Table C: 
1 = Normal
2 = Abnormal (Mild -Moderate , Severe Hy pokinesis , Akinetic and/or Dy skinetic )
3 = Unevaluable (Inadequate visualization of segments comprising allcoronary  
artery  territories due to motion artifacts, lateral wall drop out, swirling or 
attenuation artifacts) 
Table C: Overall Diagnostic Conclusion Based on LV Wall Motion
Rest StressOverall Diagnostic 
Conclusion 
1 Normal 1 Normal Normal
1 Normal 2 Abnormal Abno rmal
2 Abnormal 2 Abnormal (no change or 
worsening)Abnormal
3 Unevaluable 3 Unevaluable Unevaluable*
*A score of 3 –unevaluable at either rest or stress will result in an overall diagnostic conclusion
of unevaluable.
Separate assessments will be coll ected for unenhanced (UEUS and UE -DSE) and contrast -
enhanced (CEUS and CE -DSE).
8.6.[ADDRESS_793456]
[IP_ADDRESS] Coronary Angiography
The results of coronary  angiography  will be collected on -site for an y subject who has the 
procedure within 6 months following the LUMASON administration(s) .  All coronary  
angiograph y images should be archived and stored on dedicated digital media according to the 
standard practice at the institution.  Investigational sites are required to maintain the original
images as a record of the study . A cop y of the images shall be archived on portable digital media 
(e.g., digital versatile disc [DVD ], magnetic optical disc [MOD], com pact disc [CD], etc.) that 
will be forwarded to the central imaging laboratory  according to the instructions in the I magi ng 
Manual. If a subject does not undergo coronary  angiography  or coronary  angiography  is 
indeterminate, [ADDRESS_793457] has CAD 
based on clinical information (see Section [IP_ADDRESS] ).
A fourth blinded read er will assess the coronary  angiography  images and provide a diagnosis of 
CAD. The off-site reader will be blinded to the specifics of the protocol including the patient 
population and the results of the echocardiographic examination, but will receive clin ical 
information such as the medical history .
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793458] will be diagnosed b y the 
blinded off -site coronary  angiography  reader as Positive if percentage diameter stenosis of any of 
the vessels (R CA, LAD, LCx and LM) is ≥50%; otherwise, a subject will be considered as 
Negative.
[IP_ADDRESS] [ADDRESS_793459] not had a coronary  
angiograph y or had coronary angiograph y with indeterminate results wi thin the 6 months 
following the LUMASON administration(s).
Subjects requiring [ADDRESS_793460] cardiac events, as defined b y the 
incidence of: a) cardiac death; b) non -fatal my ocardial infarction as defined by  a greater than two 
fold serial elevation in serum creatine kinase -myocardial B (CK-MB)fraction levels; c) coronary  
revascularization; andd) documentation of the need for coron ary revascularization. If a coronary  
angiograph y is performed during the [ADDRESS_793461] study  personnel who will be responsible 
for collecting phone/clinica l record or coronary  angiograph y images during the follow up period.
8.6.[ADDRESS_793462] signs the Informed Consent and continues through the 
follow -up period defined in thesection [IP_ADDRESS] of the protocol. In addition, an investigator should 
report an y serious AEs that occur after this time period that he/she believes ma y be related to the 
IP/IMPand/or NI MP(s).
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793463] medical occurrence that occurs from the time of signed Informed Consent to the 
time immediately  prior to IP/IMPadministration will be tabulated in the Clinical Trial Report as 
a “predose event.”  
9.1 Adverse Events
9.1.1 Definitions
An adverse event (AE) is any  untoward medical occurrence in a subject or a clinical trial subject 
administered a medicinal product and which does not necessaril y have to have a causal 
relationship with the use of the product. 
Any AE that occurs after the follow -up period defined in the protocol is not required to be 
collected in the AE section of the CRF.
An existing condition, which is detected b y the diagnostic procedure conducted to test the 
efficacy  of an investigational cont rast agent, is not considered an AE.
Symptoms or medicall y significant laboratory or instrumental (e.g., electrocardiographic) 
abnormalities of a pre -existing condition, such as cancer or other disease, should not be 
considered an AE. However, new s ymptoms andlaboratory  or instrumental abnormalities, as 
well as worsening of pre -existing ones are considered AE s.
A serious adverse event (SAE) is any  untoward medical occurrence that at any  dose: 
results in death, 
is life -threatening (i.e. the subject was at risk of death at the time of the event/reaction; it 
does not refer to an event/reaction which h ypothetically might have caused death if it were 
more severe),
requires in subject hospi[INVESTIGATOR_1081], 
results in pers istent or significant disability /incapacity  (where disability  is defined as a 
permanent or substantial disruption of ability  to carry  out normal life functions, either 
reported or defined as per clinical judgment),
is a congenital anomal y/birth defect, 
isan important medical event that may  not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_599445], based upon appropriate medical 
judgment, it may jeopardize the subject and may  require medical or surgical interve ntion to 
prevent an y of the outcomes listed in the definition above.  Examples of such events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, and blood dy scrasias or convulsions that do not result in hospi[INVESTIGATOR_12191], or 
development of drug dependency  or drug abuse. 
Any suspected transmission via a medicinal product of an infectious agent is also considered a n
SAE .
A non -serious AEis an y AEthat does not meet the criteria listed above for a SAE .
The reference sa fety document will be the same for the whole clinical trial.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793464] reference document .
In particular, the sponsor will determine the expected ness of the AEs reported during this clinical 
trial according to the following reference document(s):
LUMASON : latest version of the Investigator’s Brochure (IB ),
Dobutamine: latest version of PI/SPC approved in the country  where the siteis located which
administered the NIMP to the study  subject ,
Atropi[INVESTIGATOR_050]: latest version of PI/SPC approved in the country  where the site is located which 
administered the NIMP to the study  subject.
If an updated version of the reference safet y document becomes available dur ing the conduction 
of the study and before the last subject out, the Sponsor will provide the new vers ion to all 
investigators . For Europe, the new v ersion will be provided to all i nvestigators, ECs and CAs.
The new version will become the reference safet ydocument for assessing the expectedness of 
AEs.
An AEwith fatal outcome should be considered unexpected unless the reference safet y 
document specifically  states that the ev ent might be associated with a fatal outcome. 
When it is uncertain whether an AE is expected, the AE should be treated as unexpected.
9.1.[ADDRESS_793465] report all serious adverse events within 24 hours , by [CONTACT_16062] b y fax, 
to both the Drug Safet y group and the Clinical Mana ger of the Sponsor as listed in Table D. 
A Serious Adverse Event Report (SAER, see Appendix D) must be completed by  [CONTACT_599486] (both theDrug Safety  group and the Clinical Manager) 
within [ADDRESS_793466] became aware of the serious event.  The top 
two copi[INVESTIGATOR_599446].  The 
bottom copy  remains on -site with the CRF . 
In case of death, a comprehensive narrative report of the case shoul d be prepared b y the 
Investigator and sent to both the Drug Safet y group and the Clinical Manager of the Sponsor by 
[CONTACT_599487] , with a copy retained on-site with the CRF .  If an autops y 
is performed, a cop y of the autops y report should be activel y sought b y the I nvestigator and sent 
to the Sponsor as soon as available with a copy  retained on-site with the CRF .
A follow -up SAER should be filled in by  [CONTACT_599488] -up information 
(e.g., diagnosis, outcome, cau sality  assessment, results of specific investigations) becomes
available after submission of the initial SAER .  The f ollow -up SAER should be sent to the 
Spons or in the same manner and following the same timeline as described for the initial .
If the Invest igator becomes aware of any  serious adverse events within the follow -up window 
established in the protocol following IP/IMP administration, they  will be reported to both the
Drug Safet y group and the Clinical Manager of the Sponsor as described above.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 35If outside the follow-up window established in the protocol, any serious adverse events are 
reported to the Investigator, which he/she believes are related to the administration of the IP/IMP
and/or NI MP(s), it is the Investigator’s responsibility  to report t his serious adverse event to both 
theDrug Safet y group and the Clinical Manager of the Sponsor .  Such serious adverse events 
will be reported using a Serious Adverse Event Report or an y other way chosen by  [CONTACT_3786].  Do not use the Case Report For m.
The names, telephone, fax numbers, and email address of the contact [CONTACT_599489] D.
Table D: Serious Adverse Event Reporting – Sponsor Contact [CONTACT_599490] e/Title Office Telephone 
NumberAlternate Telepho ne 
NumberFax Number / E -mail
Europe
 
 
 
 
 
* To be used outside the normal business hours .
For additional SAE questions call the Medical Expert. The contact [CONTACT_599491].
9.1.[ADDRESS_793467] s/subject s.
For each event, record the following information in the Adverse Event section of the Case Report 
Form:
Classification of the Event: Classify  the event as either serious or non -serious (see 
defin itions in Section 9.1.1).
Description of Signs or Symptoms: Whenever possible, record a specific diagnosis for 
the event.  If a diagnosis cannot be made, then record each sign or sy mptom separatel y. If 
multiple epi[INVESTIGATOR_599447], separated b y an appropriate time interval to justify  

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793468] each epi[INVESTIGATOR_599448] y 
on the Case Report Form.  I ndicate if the event is local (i.e., occurring at the site of 
administration). For serious AEs only : provide a detailed chronological description of the 
clinical course of the event(s) and of a ll relevant signs and s ymptoms.
Onset Date and Time: Record the date and time the event started.  If a change from 
predose in a laboratory  test is reported as an adv erse event, record the start date as the date 
of collection of the first lab sample that shows the change.
Stop Date and Time: Record the date and time the event resolved.  If a change from 
predose in a laboratory  test is reported as an adverse event, reco rd the stop date as the date 
of collection of the first postdose sample that shows a return to the predose level.
Intensity: 
1.Mild: Event not resulting in disability /incapacit y, which resolves without treatment.
2.Moderate: Event not resulting in disab ility/incapacity , which requires treatment.
3.Severe: Event resulting in temporary  and/or mild disability /incapacit y, which 
requires treatment.
Relationship to the IP/IMP/ NIMP :  Make every effort to determine the cause of each 
adverse event.  Classify  thecorrelation between the IP/IMP/ NIMPand the adverse event as 
follows:
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 371.Reasonable
PossibilityThe event falls into one of the two following categories:
1) a)The event follows a reasonable temporal sequence 
from administration of the IP/IMPand/or NIM P; 
AND
   b)The event follows a known response pattern to the 
IP/IMPand/or NI MP but could have been produced by  [CONTACT_599492]: 
the subject’s clinical state, or
other therap y administered, or
the diagnostic/interventional procedure ;
OR
   c)The event cannot be reasonably  explained by  [CONTACT_599493]:
the subject’s clinical state, or
other therap y administered, or
the diagnostic/interventional procedure;
OR
       d)There is evidence of partial or complete di sappearance     
of the event after withdrawal of the product (positive 
dechallenge).
2)    The report of the event contains:
       a) conflicting data 
AND/OR
       b) dubious or insufficient/poor evidence
2.No reasonable
PossibilityThe event is eith er a predose event or is definitely  due to 
causes separate from the administration of the IP/IMP , i.e.,
documented pre -existing condition
technical and manual procedural problems
concomitant medication and/orNIMP
the subject’s clinical state
the event is judged as not related and does not fall 
under either of the categories for “reasonable 
possibility ”
erroneous administration of treatment
Action Taken: 
0.None
1.Change in the IP/IMPadministration (including brief interruption of administration 
of total dose and earl y termination of administration, i.e., dose reduction)
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 382.Drug treatment required (a medication was prescribed or changed; record in the 
Concomitant Medication section of the Case Report Form)
3.Non-drug treatment required (a non -drug tre atment was prescribed or changed, record 
under “Comments” in the Adverse Event section of the Case Report Form)
4.Hospi[INVESTIGATOR_13266]
5.Diagnostic or clinical test(s) conducted (attach a copy  of the results to the Case 
Report For m) 
6.Subject discontinued from the study
Subject Outcome:  
1.Recovered without sequelae
2.Recovered with sequelae (describe the sequelae under “Comments” in the Adverse 
Event section of the Case Report Form)
3.Not Recovered, event on -going (follow th e subject until a definite outcome can be 
determined.  When follow -up data are collected, report follow -up information under 
“Comments” in the Adverse Event section of the Case Report Form; if the event is 
serious, fill in a follow -up Serious Adverse Event Report)
4.Died (list primary  cause of death under “Event Description” in the Adverse Event 
section of the Case Repo rt Form; if available, obtain a cop y of the autops y report to 
the Case Report Form and send a cop y to Sponsor )
Comments:
Provide other pert inent clinical information and observation s, and the rationale for the 
provided causality  under “Comments” in the Adverse Event section of the Case Report 
Form.  For example, record predisposing or contributing conditions, such as previous 
history , concomi tant diseases or medications, and/or procedural risks and explain the 
reasoning for attributing the event(s) to the cause chosen.
If the investigator states that there is no reasonable possibility  that the event is related, 
he/she should provide details o f an alternative explanation for the event. 
9.1.[ADDRESS_793469] report all specia l situations within 24 hours by [CONTACT_599494] , to both the Drug Safety  group and the 
Clinical Manager of the Sponsor as listed in Table D. 
Special situations include but are not limited to the following: accidental overdose of IP/IMP
and/or NIMP, medication error with IP/IMPand/or NIMP (such as administration of the wrong 
drug or wrong dose , wrong administration rate or wrong technique in drug usage process, 
administration via the wrong route, radiation under -dose, labeled drug -drug or drug -disease or 
drug-food interaction). In addition, any  notification of lactation or pregnancy  of a subject or 
partner must be reported by  [CONTACT_218255] 24 hours using the appropriate 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 39(i.e., Lactation or Pregnancy  Report )form .  Any associated SAEs must be reported concurrently  
using the SAER .  
In case urgent safet y measures are taken during the conduct of the stud y,these will be 
communicated in a timely  fashion by [CONTACT_599495] , 
IRBs/ECs/REBs and also to concerned investigators and subject s.
9.[ADDRESS_793470] sign and date each 
laboratory  report.
The central laboratory  will provide normal reference ranges for the laboratory  tests on the 
laboratory  results report.  A value is normal when it falls on or within the upper and lower limits 
of the reference range.  A value is abnormal when it falls outside the upper or lower limit of the 
reference range.  The central laboratory  will flag all abnormal values on the laboratory  report and 
will verify that the result is not due to pre -analytical problems (e.g., sample taken improperl y, 
sample stored incorrectl y, sample labeled incorrectly ) or to anal ytical problems (e.g., machine 
not accuratel y calibrated, technical problems with equipment or reagents, deterioration of 
analyte).  
The central laboratory  has established ‘alert criteria’ for some laboratory  tests and will make an 
immediate telephone call to the I nvestigator in the event that a laboratory  result meets these 
criteria.
The Investigator must evaluate an y change from predose to postdose in a laboratory  test which 
represents a worsening of the subject’s clinical state as to whether it meets the definition of an 
adverse event.  Record all changes determined to meet the definition of an adverse ev ent in 
the Adverse Event section of the Case Report Form .  
9.3.[ADDRESS_793471]’s 
clinical state and meets the definition of an adverse event, until the value returns t o the predose 
level or clinicall y stabilizes, or until the I nvestigator or phy sician of record determines that 
further follow -up is unnecessary .
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 409.3.3 Emergency Laboratory Analysis
If a laboratory  result needs to be obtained immediately , split the sample and sen d one -half to the 
local laboratory  for immediate analy sis and the other half to the central laboratory .  Attach 
results from both laboratories to the Case Report Form .
9.4 Electrocardiograms
If a worsening from predose to postdose is observed on an ECG , repeat the ECG at the discretion 
of the Investigator, in addition to obtaining an ECG at the postdose time point s required b y the 
protocol.  The Investigator will assess an y worsening from predose to postdose in the ECG for 
clinical relevance (whether it meets t he definition of an adverse event).  Record all changes 
determined to meet the definition of an adverse event in the Adverse Event section of the Case 
Report Form.
9.5 Continuous ECGs
If a worsening is observed during the continuous ECG monitoring, the Investi gator will assess 
the worsening for clinical relevance (whether it meets the definition of an adverse event).  
Record all changes determined to meet the definition of an adverse event in the Adverse Event 
section of the CRF.
9.[ADDRESS_793472] specific signs, s ymptoms ,and/or laboratory  information 
supporting these changes.
9.[ADDRESS_793473] all changes determined to meet the definition of an 
adverse event in the Adverse Event section of the Case Report Form .
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 419.8 Pulse Oximetry
If a worsening is observed during the continuous pulse oximetry  monitoring, the I nvestigator will 
assess the worsening for clinical relevance (whether it meets the definition of an adverse event).  
Record all changes determined to meet the definition of an adverse event in the Adverse Event 
section of the CRF.
10Statistical Methods
Summary  statistics (mean, median, standard deviation, minimum, and maximum) will be 
provided for continuous variables, and the number and percentage of each catego ry will be 
provided for categorical data. Unless otherwise specified, the statistical tests will be 2 -sided at 
0.05 level of significance. 
Any changes in the original statistical methodology  will be documented in the statistical analy sis 
plan (SAP). 
All statistical analy ses will be performed using SAS®software.
10.[ADDRESS_793474] been enrolled, dosed and 
completed according to the protocol. The number of subjects who prematurely  discontinued the 
study  and the reasons for their discontinuation will be summarized. Summary  statistics will be 
presented for demographic and baseline characteristics, including age, sex, race, height, weight, 
BMI, an d other relevant study  entry  criteria.
10.2 Analysis Population
Safety  Anal ysis Population –all subjects who receive LUMASON will be included in the safet y 
analysis population .
Efficacy  Anal ysis Population –all subjects who receive LUMASON , and have data avai lable at 
peak stress for both UE -DSE and CE -DSE and a definitive diagnosis (Positive, Negative) for 
CAD from truth standard (coronary  angiography  or 6 months follow -up data) will be included in 
the modified Intent -to-Diagnose (ITD) population .
10.[ADDRESS_793475]. Concomitant medications will be presented in data listings and summarized by  
[CONTACT_599496] r all subjects dosed.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 4210.4 Extent of Exposure
Descriptive statistics will be presented to summarize the volume (mL ) of IP/IMPadministered . 
Dose administration for IP /IMPwill be list ed for each injection b y subject. The peak dose of 
dobutamine and total dose o f atropi[INVESTIGATOR_599449].
10.5 Safety Analysis
The safet y data will be summarized for all subjects dosed. Summary  tables, including clinicall y 
significant changes where verapplicable, will be presented for the following safet y endpoints:
Adverse Events
Clinical L aboratory  Evaluations
Electrocardiograms
Vital Signs
Special Situations
For vital signs and ECGs, the baseline for time points at rest will be the last measurement prior 
to the IP/IMPadministration at rest ; while the bas eline for time points at stress will be the 
measurement which is collected after administration of the pharmacologic stress agent, 
dobutamine, and prior to LUMASON administration at stress (CE -DSE). All adverse events will 
be coded by [CONTACT_599497], by  [CONTACT_243696] y 
and by  [CONTACT_599498]/IMP.  Adverse event will be summarized separatel yfor the 
NIMP(s).Only those events whic h occur from the start of I P/IMPadministration through the 
follow -up peri od defined in the protocol will be tabulated in the Clinical Trial Report as “adverse 
events” see Section 9.1.1 . 
10.6 Efficacy Analysis 
The echocardiographic images will be assessed by  3 off -site blinded readers independent of the 
investigational sites; accor dingl y, the efficacy analy sis will be performed separately  for each off-
site reader. An additional , fourth, blinded reader will assess the coronary  angiography  images 
and provide a diagnosis of CAD.
10.6.1 Primary Efficacy Endpoint –Sensitivity and Specificity for Detection and 
Exclusion of CAD
[IP_ADDRESS] Truth Standard Diagnosis
For subjects with coronary angiograph y as the truth standard, a subject will be diagnosed b y the 
blinded off -site coronary  angiography  reader as Positive if percentage diameter stenosis of any of 
the vessels (RCA, LAD, LCx and LM) is ≥50%; otherwise, a subject will be considered as 
Negative. 
For the remaining subjects who didn’t have coronary  angiography  as the truth standard, a subject 
will be Positive if the subject had cardiac death, documented myocardial infarction ,documented 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 43revascularization or need for revascularization during follow up; otherwise, the subject will be 
considered as Negative.
[IP_ADDRESS] Evaluation of CAD
The overall diagnostic echocardiographic conclusion will be classified b y the off -site readers as 
Normal, Abnormal or Un evaluable for unenhanced (UEUS and UE -DSE) and LUMASON -
enhanced (CEUS and CE -DSE) echocardiograph yrespectivel y. 
The diagnostic performance of echocardiograph y(UE-DSE and CE -DSE) will be deriv ed based 
on the diagnosis from stress echocardiograph yand dia gnosis from truth standard (see Table E). 
Table E: Cross Tabulation of Diagnosis: Truth Standard vs. Stress Echocardiography
Truth Standard 
(TS)Stress Echocardiography
Normal Unevaluable * Abnormal
Negative TN FP FP
Positiv e FN FN TP
TN = true negative;  TP = true positive;  FN = false negative;  FP = false positive
*Unevaluable is defined as : inadequate visualization of segments comprising allcoronary artery territories due to 
motion artifacts, lateral wall drop out, swi rling orattenuation artifacts .
The null hy pothesis is that there is no difference in sensitivity /specificity between CE -DSE and 
UE-DSE at peak stress; the alternative h ypothesis is that CE -DSE is superior to UE -DSE in 
terms of higher sensitivity /specifici ty: 
H0:  Diag CE-Diag UE0,
Ha:  Diag CE-Diag UE> 0; 
where Diag CEand Diag UEdenote sensitivity /specificity for CE-DSE and UE -DSE at peak stress
respectivel y.
Thesensitivity  and the specifici ty along with their 95% confidence intervals (CI s) will be 
calculated, and t he difference in sensitivity /specificity  will be tested using McNemar's Chi-
square [ADDRESS_793476].
In addition, inter -reader agreement for the detection/exclusion of CAD for CE -DSE and UE -DSE 
will be evaluated by [CONTACT_599499] .
10.6.2 Co-Primary Efficacy Endpoint –Critical Shift of Subjects with Suboptimal 
Images to Adequate Images
The co -primary  endpoint:  The p roportion of subjects with suboptimal image s (≥2 adjacent 
segments with inadequate LV EBD in an y of the 3 api[INVESTIGATOR_320766]) at UE -DSE converted to 
adequate images (reduction of suboptimal adjacent segments to obtain adequate images ) at CE -
DSE will be estimated along with the 95% CIs.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 44Additionally , the following supportive anal yses will be performed:
proportion of subjects with optimal images at UE-DSE to suboptimal ( ≥2 adjacent 
segments with inadequate LV EBD in an y of the 3 api[INVESTIGATOR_320766]) at CE -DSE in terms of 
LV EBD visualization will be estimated alo ng with the 95% CIs.
The percentage of patients with at least one segment with inadequate border delineation 
will also be summarized for each of the views for both UE -DSE and CE -DSE .
Inter -reader agreement among 3 off -site readers on the critical shift of subjects with 
suboptimal images at UE -DSE to adequate images at CE -DSE will be evaluated b y kappa 
statistic.
10.6.3 Secondary Efficacy Endpoints
For the secondary efficacy  endpoint of change in total LV EBD scores at peak stress from UE -
DSE to CE -DSE , the total LV EBD score is calculated as the sum of the individual scores (0, 1, 
or 2) assigned to each of the [ADDRESS_793477] will be used to compare total L V EBD score 
between the C E-DSE and UE -DSE . Summary  statistics will be provided for the total LV EBD 
score from UE -DSE and CE -DSE . The change in total L V EBD score from UE -DSE to CE -DSE
will be summarized along with the 95% CIs and tested by  [CONTACT_54959] t -test. The cross tabulated (for 
UE-DSE vs. CE -DSE) distribution of the individual scores (0, 1, or 2) assigned to each of the 17 
ventricle segments will be presented .
Inter -reader agreement among 3 off -site readers on the EBD score for each segment from UE -
DSE and CE -DSE will be evaluat edby [CONTACT_599499].
10.6.4 Success Criteria
The study  will be considered a success if:
for th e primary  efficacy  endpoint of sensitivity /specificity , CE-DSE is superior to UE -
DSE for at least 2 out of the 3 blinded readers and for the same 2 readers a lower lim it of 
2-sided 95% CIfor sensitivity /specificit y is ≥50% (a rate considered greater than 
chance) ;
for co -primary  efficacy  endpoint of proportion of subjects with critical shift of 
suboptimal images at UE -DSE to adequate images at CE -DSE, for at least 2 ou t of the 3 
blinded readers lower limit of 2 -sided 95% CIis above 35%.
10.7 Sample Size
Software nQuery  Advisor 7.0 is used for s ample size determination in this study .
Assuggested b y FDA during the t ype C meeting on 13Aug2014, and as also reinforced and 
docum ented in the official meeting min utes issued by  [CONTACT_3955] 24Sep2014, this study  needs to 
demonstrate 1) a significant improvement in dia gnostic performance endpoints, i.e., 
sensitivity /specificity  from unenhanced stress imaging (UE -DSE) to contrast -enhanced s tress 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 45imaging (CE -DSE) in term of detection and excl usion of CAD, and 2) lower the CI of CE- DSE 
sensitivity  and specificity greater than 50% (a rate greater than chance).
For significant improvement in diagnostic performance endpoints, t he null hy pothesis is that 
there is no difference in sensitivity /specificit ybetween CE -DSE and UE -DSE at peak stress; the 
alternative h ypothesis is that CE -DSE is superior to UE -DSE in terms of higher 
sensitivity /specificity : 
H0:  Diag CE-Diag UE0,
Ha:  Diag CE-Diag UE> 0; 
where Diag CEand Diag UEdenote sensitivity /specificity for CE-DSE and UE -DSE at peak stress
respectivel y.
With 2 -sided significance level (alpha) of 5%, and the probability  of a Type II error ( ) of 0.20, 
assuming expected difference between CE -DSE a nd UE -DSE is 25%,1and the proportion of 
discordant pairs is 40%, 45 subjects will be needed for sensitivity /specificity respectivel y. 
For lower CIof CE- DSE sensitivity /specificity  greater than 50%, assuming sensitivity /specificity  
of CE-DSE = 65%, about [ADDRESS_793478] 95% confidence that the 
lower limit of sensitivity  >50%, and [ADDRESS_793479] 95% 
confidence that lower limit of specificity >50%.  
Assumi ng approximately 30% of subjects enrolled will be CAD positive,13in order to obtain [ADDRESS_793480] and if less than 30% of subjects are CAD positive, additional subj ects 
will need to be enrolled to obtain sufficient CAD positive subjects.
For the co- primary  endpoint of critical shift from suboptimal at UE -DSE images to adequate 
images at CE -DSE, sample size assumptions are based on the results from the previous pi[INVESTIGATOR_599450]- sponsored study  ( .22This study  had 44.8% -46.0% of the subjects 
converted from suboptimal at UEUS to adequate at LUMASON -enhanced echocardiograph y
(CEUS) at rest. When the sample siz e is 150, a 2 -sided 95% CI  for a single proportion using the 
large sample normal approximation will extend 8% from the observed proportion for an expected
proportion of 45% subjects with crit ical shift from suboptimal at UE -DSE images to adequate 
images atCE-DSE . This can be translated as lower limit of 95% CI  >35% for the observed 
proportion of subjects with critical shift .
Considering approximately  15% of subjects enrolled are anticipated to dropout, a pproximately  
175 subjects will need to be enrolled.
10.8 Data Handling
All data collected will be entered into the database and display ed in the data listings and /or
tables. Detail s of the data handling procedures will be specified in the SAP.

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793481] sign and personall y date an approved Informed Consent Form after receiving 
detailed written and verbal information about the reason, the nature and the possible risks 
associated with the administration of t he IP/IMPand NIMP(s).  This must be done according to 
the guidelines provided in the Declaration of Helsinki, I CH E6 Guideline for Good Clinical 
Practice, and as applicable, the requ irements of Title 21 CFR 50.20 through 50.27 and the EU 
Directive 2001/20/EC , 2005/28/EC , and related guidance , and applicable laws and regulations 
of Health Canada .
The subject must be made aware and agree that personal information may  be scru tinized during 
inspection or audit by  [CONTACT_599500] y authorized persons.  However, personal 
information will be treated as strictly  confidential and will not be publicly  available in 
accordance to the Guidelines for Data Processing within the Framework of Clinical Drug Trials 
[ADDRESS_793482]/Ethics Committee /Research Ethics Board
Approval
The protocol, Informed Consent Form, Subject Information Sheet, if applicable, and any  
advertisement for the recruitment of su bjects must be reviewed and approved by  [CONTACT_36534] y 
constituted I RB/EC /REB , as required in chapter 3 of the I CH E6 Guideline, and as applicable, 
Title 21 CFR 56.107 through 56.115 and EU Directive 2001/20/EC , 2005/28/EC, and related 
guidan ce, and applicable laws and regulations of Health Canada .Written IRB/EC /REB approval 
must be obtained by  [CONTACT_599501]/IMPor subject enrollment.  
The Investigator is committed in accordance with local requirements to inform the IRB/E C/REB
of an y emergent problem, serious adverse events, and/or protocol amendments.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 4711.4 Financial Disclosure
Financial support to Investigators/Sub -investigators other than the cost of conducting the clinical 
study  or other clinical studies will be disclosed wh ere applicable in accordance with Title 21 
CFR 54.2 to 54.6 and the EU Directive 2001/20/EC, 2005/28/EC and related guidance.
11.[ADDRESS_793483] for this study .
12Adm inistrative Considerations
12.1 Regulatory Require ments –Sponsor/Investigator Obligations
This study  will be conducted in accordance with the Declaration of Helsinki, I CH E6 Guideline, 
and as applicable, Title 21 CFR 312.50 through 312.70, and EU Directive 2001/20/EC and 
2005/28/EC related guidance , and ap plicable laws and regulations of Health Canada .To ensure 
compliance the Investigator agrees, by  [CONTACT_66692], to fully  cooperate with 
compliance checks b y allowing access to all documentation by  [CONTACT_4539], and 
competent an d regulatory authorities.
12.2 Sponsor Regulatory Obligations for S[LOCATION_003]Rs Reporting
The Sponsor shall ensure that all relevant information about suspected unexpected serious 
adverse reaction (S[LOCATION_003]R) which occurs during the course of the clinical trial, whether o r not 
this event is fatal or life -threatening, will be reported to the applicable Regulatory  
Authority /Competent Authorities including but not limited to FDA , Health Canada orany 
European Economic Area State in which the trial is being conducted and to th e relevant E Csin 
accordance with EU Directive 2011/C 172/01 about Communication from the Commission —
Detailed guidance on the collection, verification and presentation of adverse event/reaction 
reports arising from clinical trials on medicinal products f or human use (‘CT -3’).
12.3 Protocol Amendment
No change to the protocol may  be made without the joint agreement of both the I nvestigator and 
Sponsor .  Any  amendment to the original protocol will be signed b y both parties and submitted 
to the I RB/EC/Competent A uthority  (CA) /REB forapproval or notification prior to 
implementation except in circumstances when it is necessary  to implement urgent safet y 
measures to remove an immediate hazard to the study  subject(s) .
12.4 Curriculum Vitae
The Investigator and an y sub-investigator(s) must provide Sponsor with current copi[INVESTIGATOR_599451].
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 4812.5 Administrative Structure
The administrative structure of the stud y (e.g., monitoring and vendor personnel, statistician, 
laboratory  facilities, and clinic al trial supply  management) is presented in Appendix F.  A 
complete and controlled list of the I nvestigators, study  sites, and IRBs/ECs/REBs involved in 
this study  can be found in the Trial Master File maintained by  [CONTACT_1034].
12.[ADDRESS_793484] immediatel y inform Bracco.
If a violation is serious , and meet the definition of a serious breach the Clinical Research 
Manager ( CRM )takes appropriate action according to the requirements and timelines stated the 
Code of Feder al Regulations (CFR) , European Guidance and local regulations as applicable.
12.7 Monitoring Procedures
12.7.1 Study Monitoring
An appropriate representative of Sponsor (Study  Monitor) will maintain contact [CONTACT_599502]/or retrieving data.
An initiation visit will be made by  [CONTACT_599503].  The Investigator must allow the Study  Monitor to 
perform periodic, in terim monitoring visits.  The purposes of these visits are to:
verify  that written Informed Consent was obtained prior to each subject’s participation in 
the study ;
assess the progress of the study ;
review the compliance with the study  protocol;
determine whether all adverse events were appropriately  reported;
determine whether the Investigator is maintaining the essential documents;
discuss any  emergent problem;
check the Case Report Forms for legibility , accuracy  and completeness;
validate the contents of the Case Report Forms against source documents;
assess the status of IP/IMP storage, dispensing and retrieval.
All data required b y the protocol must be reported accuratel y on the Case Report Form and must 
be consistent with the source documents.  Source documents are original documents, data and 
records (e.g., hospi[INVESTIGATOR_1097], clinical and office charts, laboratory  notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_014] ,magnetic media, X -rays or other diagnostic images, subject files, laboratory  
records).  The Investigator will make available the source documents for inspection.  This 
information will be considered confidential.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 49The Study  Monitor will perform a close -outvisit at the conclusion of the Investigator’s 
involvement in the study .
12.7.[ADDRESS_793485] fails to complete the study .
If requested, copi[INVESTIGATOR_599452].
12.7.3 Inspection and Auditing
The Investigator /Institution will make available for direct access all trial related records
including source documentation for inspection by  [CONTACT_599504] , 
IRB/EC /REBand for auditing by  [CONTACT_1034].  This information will be considered confidential.
12.8 Archiving of Records
Essential documents (copi[INVESTIGATOR_18280], subject identification codes, CRF, source data, Informed 
Consent Form and other documents) pertaining t o the study conduction must be kept for the 
maximum period of time as required by [CONTACT_599505]. For 
non-European sites,this time period must be at least 2years after the last approval of the 
marketing applicati on of the IP/IMPin an ICH region and until there is no pending or 
contemplated marketing application in an ICH region or at least two years have elapsed since the 
formal discontinuation of clinical development of the IP/IMP. For EU sites ,according to EU 
Directive 2005/28/EU this time period must be at least 5years after study  completion. This period 
may be extended if required by  [CONTACT_1769].
No study  document should be destroy ed without prior written agreement between Sponsor and the 
Investigator.
Originals of all documentation and copi[INVESTIGATOR_599453] a safe area in the Trial Master File of Sponsor for the lifetime of the product. In 
particular, the final report must be retained by [INVESTIGATOR_35259] r, or the subsequent owner, for fiveyears 
beyond the lifetime of the IP/IMP.
12.9 Study Results
A final report of the study results will be written by [CONTACT_2954]. 
The Clinical Trial R eport (CTR) will be written within one y ear of the notificatio n of the end of 
study and sent to the involved ECs and CAs. It will be reviewed and approved by  [CONTACT_599506].
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 5012.10 Use and Publication of Study Results
All unpublished documentation (including the Protocol , Case Report For m and I nvestigator’s 
Brochure) given to the Investigator is strictl y confidential.  All recipi[INVESTIGATOR_599454] y person without the prior written authorization of 
Sponsor .  The submission of these docume nts to the I RB/EC/CA /REB is expressly  permitted.  
The Investigator agrees that Sponsor maintains the right to use the results of this study  in their 
original form and/or in a global report for submission to governmental, competent, and 
regulatory  authoriti es of any  country .
The results of the stud y may be presented during scientific sy mposia or published in a scientific 
journal only  after review by  [CONTACT_599507]. 
12.11 Financing
A financial agreement (separate from the protocol) will be made with the Investigator or 
designee.  Such agreement will be archived in the relevant file.
12.[ADDRESS_793486] be acceptable to both Sponsor and the 
IRB/EC /REB before the study  can be continued.
12.[ADDRESS_793487] ’s image review conducted by  [CONTACT_22885] -site 
blinded assessor (s).
12.14 Premature Termination of the Study
If Sponsor , the Investigator, or IRB/EC/CA /REB should discover conditions ari sing during the 
study  that indicate the study  should be prematurel y terminated , an appropriate schedule for 
termination will be instituted.  If the Investigator prematurel y terminates the study, an 
explanatory  letter must be provided to Sponsor .
Sponsor also reserves the right to discontinue this study  for administrative reasons at an y time.  
The Investigator will be reimbursed for reasonable expenses incurred, if it is necessary  to 
prematurel y terminate the study  or an individual subject’s participation.  Sponsor will not 
reimburse the Investigator for the evaluation of subjects if the evaluations are not conducted in 
compliance with the present protocol.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 5112.15 Information Material
Before the beginning of the study  the Investigator will be given the current versi on of reference 
safet y document, Investigator’s Brochure .  If the Investigator’s Brochure is revised during the 
study , the Investigator will receive a copy  of the revised version.  The Investigator’s Brochure
and the protocol are confidential communication s of Sponsor .  Acceptance constitutes the 
agreement by  [CONTACT_1955][INVESTIGATOR_599455] ’s prior written approval except that this document may  be disclosed to 
appropriate IRB/EC/C A/REB as long as they  are required to keep it confidential.
12.[ADDRESS_793488] subjects treated with the IP/IMP .  The I nvesti gator 
will be supplied with all data concerning the insurance compan y and policy number for a 
maximum sum insurable as stated in the Subject Information Sheet and Informed Consent Form.
13Confidentiality
All information provided to the I nvestigator dealing w ith the IP/IMP will be regarded as 
confidential.  The members of the research team agree not to discuss such information in any  
way without prior written permission from Sponsor . 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793489] this clinical study  according to th e above protocol and to make no additions or 
changes without prior consent of Sponsor and in accordance with good clinical practice and local 
requirements/regulations .
________________________________ ____ ___________________
Investigator (Signature) Date
________________________________ ____
Investigator (Printed Name)
________________________________ ____ ___________________
For Bra cco(Signature) Date
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 5315References
1Pellikka PA , Nagueh SF, Elhendy  A, Kuehl CA, Sawada SG. Ameri can Society  of 
Echocardiograph yRecommendations for Performance, Interpretation, and Application of 
Stress Echocardiograph y. J Am Soc Echocardiogr. 2007 Sep;20(9):1021 -41.
2Anantharam,B, Chahal N, Chelliah R, Ramzy  I, Gani F, Senior R:Safet y of Contrast in Stress 
Echocardiograph y in Stable Patients and in Patients With Suspected Acute Coronary  
Syndrome but Negative 12 -Hour Troponin Am J Cardiol. 2009;104:14 –18.
3Gaibazzi N, Rigo F, Reverberi C. Detection of Coronary  Artery  Disease by [CONTACT_599508], My ocardial Perfusion and Coronary  Flow Reserve: A 
Multiparametric Contrast Stress -Echocardiography Study . J Am Soc Echocardiogr 
2010;23:[ADDRESS_793490] for left ventricular opacification and border definition on sensitivity  and specificit y of 
dobutamine stress echocardiograph y compared with coronary angiograph y in technicall y 
difficult patients. Am Heart J .2001;142:[ADDRESS_793491] and Stress Echocardiography . J 
AM Coll Cardiol. 2009;53(1):[ADDRESS_793492] on the diagnostic 
accuracy  of Dobutamine Echocardiography  in coronary  artery  disease. J Am Coll Cardioll 
Img 2008;1:145 -52.
7Douglas PS, Hoffmann U, Patel MR, Mark DB, Al -Khalidi HR, Cavanaugh B, et al. Outcomes 
of Anatomical versus Functional Testing for Coronary  Artery  Disease. N Eng J Med. 
2015;372: 1291 -1300.
8Gibbons RJ. Noninvasive Diagnosis and Prognosis Assessment in Chronic Coronary Artery 
Disease: Stress Testing with and without I maging P erspective. Circ Cardiovasc Imaging 
2008;1:257 -69.
9Kim C, Kwok YS, Heagerty  P, Redberg R. Pharmacologic Stress testing for Coronary  Disease 
diagnosis: A Meta -analysis. Am Heart J 2001;142:934 -944.
10Krivok api[INVESTIGATOR_69936] J, Child JS, Walter DO, Garfinkel A. Prognostic Value of Dobutamine Stress 
Echocardiograph y in Prediciting Events in Pateints with Known or Suspected Coronary 
Artery  Disease. J Am Coll Cardiol 1999;33:708 -16.
11Marwick , TH. Education in Heart Stress Echocardiograph y. Heart 2003; 89:113-118.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793493] Agents in Echocardiograph y. J Am Soc Echocardiogr. 2008 
Nov;21(11):1179-201.
13Senior R, Becher H, Monaghan M, Agati L, Zamorano J,Vanoverschelde JL , et al. EAE 
recommendations Contrast echocardiograph y: Evidence -based recommendations by  [CONTACT_599509] y.Europea n Journal of Echocardiography  2009 ;10:194–212.
14Brown AS, Calachinas M, Evdoridis C, Hancock J, Wild S, Prasan A, et al: SonoV ue 
improves endocardial border detection and variability  in assessing wall motion score and 
ejection fraction during stress echocardiography . Irish Journal of Medical Sciences. 
2004;173(1):[ADDRESS_793494] echocardiography  improves the accuracy  and reproducibility  of left ventricular 
remodeling measurements: a prospective randomly assigned, blinded stud y. J Am Coll 
Cardiol. 2001;38:[ADDRESS_793495] enhancement on transthoracic echocardiographic assessment of left ventricular 
regional wall motion. Am J Cardiol. 1999;84:[ADDRESS_793496] imaging in difficult to image patients J Am Soc Echocardiogr. 
2000:13:[ADDRESS_793497] enhanced 
quantitation of left ventricular ejection fraction: what is the best method? J Am Soc 
Echocardiogr. 2001;14:1183-90.
19Rainbird AJ, Mulvagh SL, Oh JK, McCully  RB, Klarich KW, Shub C, et al. Contrast 
dobutamine stress echocardiograph y: Clinical practice assessment in 300 consecutive patients. 
J Am Soc Echocardiog 2001;14:378 -85.
20Douglas PS, Khandheria B, Stainback RF, Weissman NJ. 
ACCF/ASE/ACEP/AHA/ASNC/SCAI /SCCT/SCMR 2008 appropriateness criteria for stress 
echocardi ograph y. J Am Coll Cardiol 2008;51:1127– 47.
21Sicari R , Nihoy annopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Polderman D, et al. 
EAE GUIDE LINES .Stress echocardiograph y expert consensus statement .European 
Association of Echocardiograph y (EAE) (a registered branch of the ESC) . Eur J 
Echocardiogr. 2008;9:415 –37.
22Bracco Final Clinical Trail Report 
23Bracco Final Clinical Trail Report 

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 5524Bracco Final Clinical Trail Report 
25Bracco Final Clinical Trial Report 
26Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al. 
ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI /SCCM /SCCT/ SCMR 2011 Appropriate Use 
Criteria for Echocardiography . A Report of the American College of Cardiology  Foundation 
Appropriate Use Criteria Tas k Force, American Society  of Echocardiography , American 
Heart Association, American Societ y of Nuclear Cardiology, Heart Failure Society of 
America, Heart Rhy thm Society , Societ y for Cardiovascular Angiograph y and Interventions, 
Society  of Critical Care Me dicine, Societ y of Cardiovascular Computed Tomograph y, Society 
for Cardiovascular Magnetic Resonance . J am Coll Cardiol 2011;57(9):1126 -66.
27Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P, et al. Recommendations 
for chamber quantification: a report from the American Societ y of Echocardiograph y’s 
guidelines and standards committee and the chamber quantification writing group, developed 
in conjunction with the European Association of Echocardiograph y, a branch of the European 
Society  of Ca rdiology . J Am Soc Echocardiogr 2005;18:1440-63.
28Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL , et al.
ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiograph y: 
Summary  article. A report of the America n College of Cardiology /American Heart 
Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 
1997 Guidelines on the Clinical Application of Echocardiograph y) J Am Coll Cardiol. 
2003;42:954 –970.
29Mieres JH, Shaw L J, Arai A, Budoff MJ, Flamm SD, Hundley  WG, et al. Cardiac Imaging 
Committee, Council on Clinical Cardiology , and the Cardiovascular Imaging and Intervention 
Committee, Council on Cardiovascular Radiology and Intervention, American Heart 
Association Role of noninvasive testing in the clinical evaluation of women with suspected 
coronary  artery  disease: Consensus statement from the Cardiac Imaging Committee, Council 
on Clinical Cardiology , and the Cardiovascular Imaging and Intervention Committee, Council 
on Cardiovascular Radiology  and Intervention, American Heart Association. Circu lation. 
2005;111:682–96.
30Senior R, Dwivedi G, Hay at S, L im TK. Clinical benefits of contrast -enhanced 
echocardiograph y during rest and stress examinations. Eur J Echocardiography .2005;6 (Suppl
2):S6-S13.
31Cosy ns B, Roosens B, Hernot S, El Haddad P, L ignian H, Pi[INVESTIGATOR_554202] L, et al. Use of contrast 
echocardiograph y in intensive care and at the emergency  room. Curr Cardiol Rev. 
2011(7);157-62.
32Paterson I, Mielniczuk LM, O'Meara E, So A, White JA. I maging heart failure: current and 
future applications. Can J Cardiol. 2013 Mar;29(3):317-28.

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793498] pain: sy stematic review of evidence base and cost -effectiveness. J 
Thorac Imaging. 2012 Sep;27(5):289 -95.
34Douglas PS, Patel MR, Bailey  SR, Dai D, Kaltenbach L, Brindis RG, et al. Hospi[INVESTIGATOR_599456], diagnostic coronary  
angiograph y.J Am Coll Cardiol. 2011 ;58:801 -809.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 57Appendix A: Investigational Product /Investigational Medicinal Product
Labeling
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793499] /Investigational Medicinal Product Labeling
North America
The following 2-part label will be applied to the kit:
LUMASON KitLabel
Lumason™
IND 46,958 Protocol No. BR1-142
Contents:
1 Lumason™ vial of 25 mg ly ophilized powder
1 pre -filled sy ringe of5 mL Sodium Chloride injection USP,
0.9% Sodium Chloride (DILUENT)
1 mini -spi[INVESTIGATOR_599457] a t 25 C (77 F) excursions permitted to 15 -30C (59 -
86F) 
CAUTION: New Drug -Limited by  [CONTACT_599510].: Exp. Date :
Bracco Diagnostics Inc., Monroe Twp , NJ 08 831Lumason™
IND 46,958 Protocol No. BR1-142
Contents:
1 Luma son™ vial of 25 mg ly ophilized powder
1 pre -filled sy ringe of5 mL Sodium Chloride injection USP,
0.9% Sodium Chloride (DILUENT)
1 mini -spi[INVESTIGATOR_599458] 25 C (77 F) excursions permitted to 15 -30C (59 -
86F) 
CAUTION: New Drug -Limited by  [CONTACT_599510].: Exp. Date :
Bracco Diagnostics Inc., Monroe Twp , NJ 08 831
The following 2 -part label will be positioned on each vial of LUMASON:
LUMASON 2 -Part Vial Label 
Lumason™ 25mg Protocol :  BR1 -142
Store at 25 C (77 F) excursions permitted to 15 -30C (59 -
86F)
For i.v. use after reconstitution with 5 mL of saline .
CAUTION: New Drug -Limited by  [CONTACT_33839] .
Subject No.
Batch No.: Exp. Date :
Bracco Diagnostics Inc., Monroe Twp , NJ 08 831Lumason™ 25mg Protocol:  BR1 -142
Store at 25 C (77 F) excursions permitted to 15 -30C (59 -
86F)
For i.v. use after reconstitution with 5 mL of saline
CAUTION: New Drug -Limited by  [CONTACT_33839] .
Subject No.
Batch No.: Exp. Date :
Bracco Diagnosti cs Inc., Monroe Twp , NJ 08 831
The above labels are “ master labels. ”  The actual labels used for each country  are filed in the 
Trial Master File of the study .
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 59Europe
The following label will be applied to the kit which includes 2 clear plastic containers :
SonoVue Kit Label
SonoVue®(BR1) -8 µl/mL     
Dispersion for intravenous injection after reconstitution              Code number. Lxxx/xx
Study No. BR1 -[ADDRESS_793500] No . 
Content: 2 vials of 25 mg lyophilized powder ( SonoVue®)
2 pre -filled sy ringes with 5 mL NaCl 0.9% w/v
Batch No.:xxxxx/xxxxx Expi[INVESTIGATOR_5695]: mm/ yyyy –mm/yyyy
Direction for use: Administer within [ADDRESS_793501]
Sponsor: Bracco Imaging S.p.A. (+39 -02-2177.1) Via F olli, 50 -I -[ZIP_CODE] Milano
IMP Man ufacturer: Bracco Imaging S.p.A. (+39 -0125 -[ZIP_CODE].1) Via Ribes, 5 -I -[ZIP_CODE] Colleretto Giacosa 
The following 2 -part label will be positioned on each vial of SonoVue:
SonoVue Vial Label
SonoVue®(BR1) -8 µl/mL         Code No. Lxxx/xx
25 mg ly ophilized pow der to be reconstituted 
with 5 mL NaCl 0.9% -For intravenous injection 
after reconstitution
Study N o. BR1 -[ADDRESS_793502] No .
Batch No: Exp. Date: mm/yyyy
No special storage conditions are required. 
FOR CLINICAL TRIAL USE ONLY
Sponsor: Bracco I maging S.p.A -I -[ZIP_CODE] MilanoSonoVue®(BR1) -8 µl/mL         Code No. Lxxx/xx
25 mg ly ophilized powder to be reconstituted 
with 5 mL NaCl 0.9% -For intravenous injection 
after reconstitution
Study N o. BR1 -[ADDRESS_793503] No .
Batch No: Exp. Da te: mm/yyyy
No special storage conditions are required. 
FOR CLINICAL TRIAL USE ONLY
Sponsor: Bracco Imaging S.p.A -I -[ZIP_CODE] Milano
The above labels are “ master labels. ”  The actual labels used for each country are filed in the 
Trial Master File of th e study .
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 60Appendix B: LUMASON /SONOVUE Reconstitution
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 61LUMASON Reconstitution
LUMASON is supplied within a kit containing the following: 
a clear glass vial labeled as LUMASON (sulfur hexafluoride lipid microsphere) for 
Injectable Suspension,
a prefilled s yringe labeled as Sodium Chloride I njection, USP, 0.9% Sodium Chloride 
(DILUENT), and 
a Mini -Spi[INVESTIGATOR_2531] .  
Glass vial Prefilled sy ringe and 
its plunger rodMini -Spi[INVESTIGATOR_599459]:
Prior to L UMASON reconsti tution, inspect the kit and its components for signs of damage.  Do 
not use the kit if the protective caps on the vial and prefilled s yringe are not intact or if the kit 
shows other signs of damage.  
Perform all LUMASON reconstitution steps under aseptic conditions.  The LUMASON vial 
and the prefilled sy ringe do not contain a bacteriostatic preservative.  
LUMASON is reconstituted by  [CONTACT_599511] (5 mL saline) into the 
LUMASON vial using the following illustrated steps below.  
1. Connect the plunger rod to the prefilled 
syringe barrel by  [CONTACT_599512] i nto the 
syringe (see Figure 1).
Figure 1.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 62LUMASON Reconstitution (continued)
2. Open the Mini -Spi[INVESTIGATOR_599460] (see Figure 2).
Figure 2.
3. Open the Mini -Spi[INVESTIGATOR_599461] -Spi[INVESTIGATOR_599462] (see Figure 3).
Figure 3.
4. Remove the flip cap plastic protective cap 
from the vial, remove the Mini -Spi[INVESTIGATOR_599463]. Press firmly  
inward until the spi[INVESTIGATOR_599464] (see Figure 4).
Figure 4.
5. Empty  the content of the sy ringe into the vial 
by [CONTACT_599513] t he plunger rod (see Figure 5). 
Figure 5.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 63LUMASON Reconstitution (continued)
6. Shake vigorously  for 20 seconds, mixing all 
the contents in the vial (see Figure 6). A 
homogeneous white milky  liquid indicates 
formation of sulfur hexafluoride lipid 
microspheres. 
Figure 6.
7. Invert the s ystem and slowly  withdraw the 
needed volume of suspension i nto the sy ringe 
(see Figure 7).
Figure 7.
8. Unscrew the s yringe from the Mini -Spi[INVESTIGATOR_2531] 
(see Figure 8). Immediately  connect the s yringe 
to the dose administration line (20 G) and 
administer as dire cted under Section 6.4.
Figure 8.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 64SONOVUE Reconstitution
1
v1.0-08/200 0 ©BRG 2000
2 3
4 5
6 7 8
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793504].
5.Empty  the contents of the sy ringe into the vial by  [CONTACT_599514].
6.Shake vigorously  for 20 seconds to mix all the contents in the vial to obtain a white milky  
homogeneous liquid.
7.Invert the s ystem and carefully  withdraw SONOVUE into the sy ringe.
8.Unscrew the s yringe from the transfer s ystem.
Do not use if the liquid obtained is clear and/or if solid parts of the lyophilisate are seen in 
the suspension.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR-AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 66Appendix C: Study Schedule 
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress Echocardiography Lumason™
Document ID: BDI-PTR -AC2940.[ADDRESS_793505] Stress
Follow -Up UEUS IP/IMP CEUS
STRESSORUE-DSE IP/IMP CE-DSE
Within -24 hr -1 hr -10 min Immed prior 0 min 30 min Immed prior 0 min 30 min 1 hr 24 hr 72 hr 6 mos
Written Informed Consenta
Pregnancy Test (if necessary) 
Adverse Events Monitoringb            
Concomita nt Medicationsc           
Medical History d
Physical Examination  
Vital Signse,f     
Laboratory Evaluationsg 
Electrocardiogram -discretef     
Electrocar diogram –continuous        
Pulse oximetry        
IP/IMP Administration  
Imaging Procedure    
Dobutamine Administration h
Truth Standard   
Follow -up Contact f or AE 
aObtain prior to implementation of any study procedure.
bStart monitoring from the time of signing Informed Consent up to [ADDRESS_793506] adver se events for L UMASON and 
NIMPs (dobutamine, a tropi[INVESTIGATOR_050]).
cRecord all medications (prescription and over -the-counter) taken within [ADDRESS_793507] LUMASON administratio n. 
dIncludes Demograp hics, Cardiac Medical History and General Medical History.
eIncludes systolic and diastolic blood pressure, heart rate.
fIf stress echocardiography (CE -DSE) is not performed, obtain at [ADDRESS_793508] blood samples according to the instruction manual from the central laboratory.
hAtropi[INVESTIGATOR_599465] d obutamine if needed to achieve peak stress.
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 68Appendix D: Serious Adverse Event Report
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 69

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 70

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 71

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 72

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 73

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 74

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 75

Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 76Appendix E: Investigator Statement
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
INVESTIGATOR STATEMENT Page 1of 2
Document ID: BDI-PTR -AC2940.[ADDRESS_793509] Lumason™ /SonoVue®
Protocol No. BR1 -142
Protocol 
Title:A Prospective Multicenter Phase III Clinical Evaluation of 
the Safety and Efficacy of Lumason /SonoVue in Subjects 
Undergoing Pharmacologic Stress Echocardiography with 
Dobutamine for the Diagnosis of Coronary Artery Disease
Investigator:
Study Site:
COMMI TMENTS
By [CONTACT_17137], I  agree to conduct the study  as outlined in the protocol and in 
accordance wi th:Title 21 CFR 56 -Institutional Review Boards, the European Directive 
2001/20/EC , 2005/28/EC and related guidance, and the Declaration of Helsinki, as well as, all 
applicable government regulations, Good Clinical Practice and also
I declare:
1)I am well qualified b y scientific training and experience to conduct investigational studies in 
the clinical area of the proposed study  and I am affiliated with a recognized medical school 
or with an independent institution recognized for its excellence.
2)I have rece ived and understand the information about pharmacology , toxicology  and possible 
risks and side effects of the investigational product (e.g., as described in the Reference Safet y 
Information ).
3)I shall provide information to all staff members involved in the study  about their obligations 
as described in this document.
4)I shall submit the protocol, I nformed Consent Form/Subject I nformation Sheet and other 
required documentation to the I RB/EC for review and approval.
5)I shall make no changes to the protocol witho ut formal amendment (prepared in agreement 
with the Sponsor), except when necessary  to protect the safet y, the rights or welfare of 
subjects. In this last case I will inform the Sponsor of the change .I shall report serious 
breaches according to applicable regulations.
6)I shall require Informed Consent from each subject prior to enrollment into the study.  The 
Informed Consent shall be documented b y use of a written consent form approved b y the 
IRB/EC. I shall also require a Data Protection Form .
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
INVESTIGATOR STATEM ENT Page 2of 2
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 787)I shall use the investigational product only  in compliance with the study  protocol and I shall 
be responsible for the security  and accountability  of clinical study  supplies.
8)I shall notify  the Sponsor immediately  or no later than 24 hours by  [CONTACT_18623]/or b y fax o f 
serious adverse events and submit written reports of serious adverse events, as outlined in the 
protocol, to Sponsor .
9)(for sites outside the European Economic Area, add the following) I shall submit a written 
report of adverse events to the I RB/EC, as r equired by  [CONTACT_428239].
10)I shall complete the Sponsor’s Case Report Form (CRF) in a timely  and legible manner.
11)I shall maintain accurate source records (hospi[INVESTIGATOR_599466]), which will 
support the data entered int o Case Report Forms and I  shall maintain these as specified in the 
protocol.
12)I shall retain essential documents (Investigator’s files) including stud y codes for at least 5 
years(or longer if required by  [CONTACT_599515]) after completion or 
discontinuation of the trial and, in an y case, no documentation will be destroy ed without 
prior written agreement with the Sponsor.
13)I shall allow monitoring visits by  [CONTACT_2728] ’s representatives a predetermined frequency .
14)I shall allow the authorized Spo nsor representative and an y competent and regulatory  
authorities to inspect the facilities and pertinent records at reasonable times and in a manner 
which ensure subject confidentiality .
15)I shall maintain confidentiality  about all information concerning the investigational product, 
such as patent applications, formulas, manufacturing process, basic scientific data and 
formulation information supplied by  [CONTACT_599516] I shall not 
disclose this information to a third part y withou t the written consent of the Sponsor.
16)I shall permit the information developed in the clinical study  to be used by  [CONTACT_599517]/EC and competent and regulatory authorities.
Following completion of the study , the data may  be considered for reporting at a scientific 
meeting and/or for publication in a scientific journal.  A cop y of the manuscript or abstract will 
be provided to the Sponsor for review before submis sion to a scientific journal for publication 
and/or a scientific meeting selection committee for oral or poster presentation.  Subgroup or 
individual I nvestigator publications must not interfere or compromise publication of the multi -
center results of this clinical study .
________________________________ ____ ___________________
Investigator Date
________________________________ ____
Investigator (Printed Name)
Protocol BR1 -142
Final Version
30April 2015Lumason™/SonoVue ®in Stress 
EchocardiographyLumason™
Document ID: BDI-PTR -AC2940.14 -BR142PT -B044389 -1.0
Confidential Page 79Appendix F: Adm inistrative Structure 
Adm inistrative Structure
North America
Clinical Research Personnel
 
CROs
Study Monitoring Central Laboratory
Central ECG Laboratory Central Imaging Laboratory
TBD TBD
Europe
Clinical Research Personnel
CROs
Study Monitoring Central Laboratory
TBD
Central ECG Laboratory Central Imaging Laboratory
TBD TBD
